NAME,DESCRIPTION,SEQAPASS,GENE_SYMBOLS,GENE_NAMES,GENE_URLS,AOP,EVENT,HIT_CALL,TOP,SCALED_TOP,AC50,LOGAC50,BMAD,MAXMED,MAXMED_UNITS,MAXMEDCONC,CUTOFF,FLAGS,MODLACC,MODLAC10,MODLACB,STOCK_CONCENTRATION,INTENDED_TARGET_FAMILY
ACEA_AR_agonist_AUC_viability,"Data from the assay component ACEA_AR_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,147.792889417013,5.500413649686517,10.465040630184474,1.01974091881237,8.95647120560566,147.748043305299,percent_activity,2,26.869413616817,,0.884839121649436,0.884839121649436,0.822682288938975,20,cell cycle
ACEA_AR_antagonist_80hr,"Data from the assay component ACEA_AR_antagonist_80hr was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of growth reporter, measures of the cells for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,,,Active,2.86088309791299,7.815591297575992,8.083701475661382,0.907610267007191,0.122016065451132,2.85986524216955,log2_fold_induction,1.30102999566398,0.366048196353396,,0.80342059789727,0.80342059789727,0.788327976565574,20,nuclear receptor
ACEA_AR_antagonist_AUC_viability,"Data from the assay component ACEA_AR_antagonist_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,129.344347065234,4.467732190800585,10.139042406276843,1.00599693948368,9.65026114229828,128.969007342281,percent_activity,2,28.9507834268948,,0.844392333300911,0.844392333300911,0.720446979968601,20,cell cycle
ACEA_ER_AUC_viability,"Data from the assay component ACEA_ER_AUC_viability was analyzed  in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of growth reporter, loss-of-signal activity can be used to understand changes in the viability. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,108.22960651996029,5.411480325998014,21.436870672814866,1.3311613878901396,5.860768439731081,108.22935794981564,percent_activity,2,20,,1.2505882850160626,1.2421264394539604,1.2118809860781823,20,cell cycle
APR_HepG2_CellLoss_1h_dn,"Data from the assay component APR_HepG2_CellLoss_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,3.51652944164769,6.3136635149851275,116.58866224808676,2.06665631918371,0.0556971310444626,3.87287813133156,log2_fold_induction,2.30102999566398,0.556971310444626,,1.83065717300202,1.64305881968449,1.75620378977221,20,cell cycle
APR_HepG2_CellLoss_24h_dn,"Data from the assay component APR_HepG2_CellLoss_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,2.09690870394952,3.167431821215385,41.64924068039085,1.619607088064,0.066202173316075,1.92610659462248,log2_fold_induction,2.30102999566398,0.66202173316075,,1.4723595695732,1.18990243346117,1.20135512612544,20,cell cycle
APR_HepG2_CellLoss_72h_dn,"Data from the assay component APR_HepG2_CellLoss_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_CellLoss_72h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.51232111086402,1.7042554380617578,21.552420126012223,1.3334960442582,0.0887379366431112,1.43598524771979,log2_fold_induction,1.69897000433602,0.887379366431112,"[""Cell viability assay fit with gnls winning model"",""Cell viability assay fit with gnls winning model""]",1.37268150827565,1.16099307748344,1.0879290456186,20,cell cycle
APR_HepG2_MicrotubuleCSK_72h_up,"Data from the assay component APR_HepG2_MicrotubuleCSK_72hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_MicrotubuleCSK_72h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of conformation reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,2.70045035057856,2.600599280615567,21.968490391132203,1.34180021452968,0.103839540782283,2.25037529220858,log2_fold_induction,2,1.03839540782283,,1.22684345633951,0.843938415043857,0.804815585945031,20,cell morphology
APR_HepG2_MitoMembPot_1h_dn,"Data from the assay component APR_HepG2_MitoMembPot_1hr was analyzed into 2 assay endpoints. This assay endpoint, APR_HepG2_MitoMembPot_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,2.99585976277139,1.6769164314524287,42.44999721099853,1.62787766604645,0.17865289567093,2.59989102313274,log2_fold_induction,2,1.7865289567093,"[""Hit-call potentially confounded by overfitting"",""Hit-call potentially confounded by overfitting""]",1.70522053609085,1.32584201883672,1.19236662300906,20,cell morphology
APR_HepG2_NuclearSize_1h_dn,"Data from the assay component APR_HepG2_NuclearSize_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_1h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,0.466478903619182,1.7734520400116034,115.86631735950796,2.06395720377273,0.00761052381278775,0.388732419686571,log2_fold_induction,2.30102999566398,0.263034405833794,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",2.10326499860691,1.6099846873299,1.72775295291395,20,cell morphology
APR_HepG2_NuclearSize_24h_dn,"Data from the assay component APR_HepG2_NuclearSize_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_NuclearSize_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, measures of all nuclear dna for loss-of-signal activity can be used to understand the signaling at the nuclear-level. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""organelle conformation"".",, , , ,,,Active,0.89687285728859,3.4097168940526563,74.78546969314328,1.87381722560396,0.0102845399297649,0.826239421032209,log2_fold_induction,2.30102999566398,0.263034405833794,,1.72239061724189,1.29968433337161,1.49551732907449,20,cell morphology
APR_HepG2_p53Act_1h_up,"Data from the assay component APR_HepG2_p53Act_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3, , , ,"[46,46]",,Active,1.00872877022393,1.1969949104304531,109.08681338825008,2.03777225545689,0.0842717676937473,0.907915961378756,log2_fold_induction,2.30102999566398,0.842717676937473,"[""Borderline active"",""Borderline active""]",2.23241539707367,1.90654652839107,1.77451936380189,20,dna binding
APR_HepG2_p53Act_24h_dn,"Data from the assay component APR_HepG2_p53Act_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_p53Act_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene TP53. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""dna binding"" intended target family, where the subfamily is ""tumor suppressor"".",NP_000537.3, , , ,"[46,46]",,Active,2.012914982769982,2.0712098803946843,115.77972778907365,2.063632524157696,0.09718546641861357,1.98782798570558,log2_fold_induction,2.30102999566398,0.9718546641861358,,2.0598982029300212,1.9672389275729314,1.94435221028937,20,dna binding
APR_HepG2_P-H2AX_1h_up,"Data from the assay component APR_HepG2_P-H2AX_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1, , , ,,,Active,3.21594627722623,4.168152268100691,99.70488139885043,1.99871642122729,0.0771552014027464,2.67995523102205,log2_fold_induction,2.30102999566398,0.771552014027464,,1.77550111126419,1.50380560192844,1.57339899744612,20,dna binding
APR_HepG2_P-H2AX_24h_up,"Data from the assay component APR_HepG2_P-H2AX_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_P-H2AX_24h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is cellular response to DNA damage stimulus.",NP_002096.1, , , ,,,Active,3.3519750353579,4.082150182495743,70.06877093314193,1.84552449965947,0.0821129768750588,3.03049021932314,log2_fold_induction,2.30102999566398,0.821129768750588,,1.61843531258127,1.33425029340886,1.40224645361042,20,dna binding
APR_HepG2_StressKinase_1h_up,"Data from the assay component APR_HepG2_StressKinase_1hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_1h_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for gain-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",NP_002219.1, , , ,,,Active,1.15869557612608,1.4640714368917702,37.538420121641835,1.57447599053116,0.0791420108970909,0.965579646774902,log2_fold_induction,2,0.791420108970909,,1.78393671080116,1.2045387038481,0.974994183332711,20,cell cycle
APR_HepG2_StressKinase_24h_dn,"Data from the assay component APR_HepG2_StressKinase_24hr was analyzed into 2 assay endpoints. 
This assay endpoint, APR_HepG2_StressKinase_24h_dn, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of enzyme reporter, measures of protein for loss-of-signal activity can be used to understand the signaling at the pathway-level as they relate to the gene . 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""stress response"".",NP_002219.1, , , ,,,Active,5.05811170395911,5.4730110158547065,106.79407892788649,2.02854717441322,0.0924191763785295,4.21509308676649,log2_fold_induction,2.30102999566398,0.924191763785295,,1.77177581166545,1.54049127212473,1.65193764214347,20,cell cycle
ATG_PXRE_CIS_up,"Data from the assay component ATG_PXRE_CIS was analyzed into 1 assay endpoint. 
This assay endpoint, ATG_PXRE_CIS_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, measures of mRNA for gain-of-signal activity can be used to understand the reporter gene at the transcription factor-level as they relate to the gene NR1I2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,"[8,11,60,8,11,60]",,Active,2.595432986053304,3.894677876731014,1.6165539892581968,0.2085902136462264,0.13328100901796647,2.4598652472209945,log2_fold_induction,0.602059991327962,0.6664050450898323,,0.06428787653861445,-0.02263781360619918,-0.08971860807859747,20,nuclear receptor
BSK_3C_Eselectin_down,"Data from the assay component BSK_3C_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,1.0290526600842265,12.99616653500611,10,1,0.022749058062569997,1.029,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.883859816213064,20,cell adhesion molecules
BSK_3C_HLADR_down,"Data from the assay component BSK_3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.9882362259226951,12.4806854558503,10,1,0.025758990402599997,0.988,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7805365337847713,20,cell adhesion molecules
BSK_3C_ICAM1_down,"Data from the assay component BSK_3C_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2, , , ,,,Active,1.0151704839080604,12.820845017991633,10,1,0.016926969131288997,1.015,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,1.009225444220384,20,cell adhesion molecules
BSK_3C_IL8_down,"Data from the assay component BSK_3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,1.0950673588675481,11.085736350291329,10,1,0.0329272175904,1.095,log10_fold_induction,1.60205999132796,0.0987816527712,"[""Hit-call potentially confounded by overfitting""]",1,1,0.9566031604665964,20,cytokine
BSK_3C_MCP1_down,"Data from the assay component BSK_3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,1.3462554489490113,15.882523564976017,10,1,0.028254440453399997,1.346,log10_fold_induction,1.60205999132796,0.08476332136019998,"[""Hit-call potentially confounded by overfitting""]",1,1,1.0176782665206483,20,cytokine
BSK_3C_MIG_down,"Data from the assay component BSK_3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,1.286288469884982,16.24486269275585,10,1,0.00716423639925,1.286,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,1.02658668166242,20,cytokine
BSK_3C_Proliferation_down,"Data from the assay component BSK_3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.9682829629346852,8.243984071073035,10,1,0.0391510930713,0.968,log10_fold_induction,1.60205999132796,0.1174532792139,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7798534670795152,20,cell cycle
BSK_3C_SRB_down,"Data from the assay component BSK_3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.058709916501158,13.370715533630023,10,1,0.02172150128694,0.973,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.8469596701001603,20,cell cycle
BSK_3C_TissueFactor_down,"Data from the assay component BSK_3C_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.5879999999777255,4.516453539812882,39.99999999999999,1.6020599913279623,0.04339688170481999,0.49,log10_fold_induction,1.60205999132796,0.13019064511446,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.8677669151472513,20,cytokine
BSK_3C_uPAR_down,"Data from the assay component BSK_3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.8131174978517886,6.935341200862223,39.99999999999999,1.6020599913279623,0.0390808697223,0.813,log10_fold_induction,1.60205999132796,0.1172426091669,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.0040731843340036,20,cytokine
BSK_3C_VCAM1_down,"Data from the assay component BSK_3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,1.0320341471876118,13.033820490358012,10,1,0.0189344513925,1.032,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.9146053379908988,20,cell adhesion molecules
BSK_3C_Vis_down,"Data from the assay component BSK_3C_Vis was analyzed into 2 assay endpoints. This assay endpoint, BSK_3C_Vis_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of morphology reporter, loss-of-signal activity can be used to understand changes in the background control. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a background control function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell morphology"" intended target family, where the subfamily is ""cell conformation"".",, , , ,,,Active,1.0001067988325087,12.630601926003774,10,1,0,1,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.9863635733025319,20,cell morphology
BSK_4H_Eotaxin3_down,"Data from the assay component BSK_4H_Eotaxin3 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Eotaxin3_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL26. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_006063.1, , , ,,,Active,1.08631786375135,13.356827293826623,39.99999999999999,1.6020599913279623,0.027110177186399995,1.086,log10_fold_induction,1.60205999132796,0.08133053155919999,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0409070746620364,20,cytokine
BSK_4H_MCP1_down,"Data from the assay component BSK_4H_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.7667999999795696,4.75043882681753,10,1,0.05380555551,0.639,log10_fold_induction,1.60205999132796,0.16141666653,"[""Hit-call potentially confounded by overfitting""]",1,1,0.42348919603707247,20,cytokine
BSK_4H_Pselectin_down,"Data from the assay component BSK_4H_Pselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_Pselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELP. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_002996.2, , , ,,,Active,0.8175249619218873,6.668764550153905,10,1,0.04086338910171,0.752,log10_fold_induction,1.60205999132796,0.12259016730513,"[""Hit-call potentially confounded by overfitting""]",1,1,0.6879711696369932,20,cell adhesion molecules
BSK_4H_SRB_down,"Data from the assay component BSK_4H_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_4H_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0941378730961784,13.818144165577943,10,1,0.02048812375239,1.094,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.9954274475420032,20,cell cycle
BSK_4H_uPAR_down,"Data from the assay component BSK_4H_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.8159999890743337,7.381660592519548,39.99999999999999,1.6020599913279623,0.03684807679098,0.68,log10_fold_induction,1.60205999132796,0.11054423037293999,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.395413682017529,20,cytokine
BSK_4H_VCAM1_down,"Data from the assay component BSK_4H_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,1.144799999970257,14.457968990304837,10,1,0.0228833401839,0.954,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,1.0158260052039918,20,cell adhesion molecules
BSK_4H_VEGFRII_down,"Data from the assay component BSK_4H_VEGFRII was analyzed into 2 assay endpoints. This assay endpoint, BSK_4H_VEGFRII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene KDR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",NP_002244.1, , , ,"[43,43]",,Active,0.3401398577525207,3.2504679275741637,39.99999999999999,1.6020599913279623,0.03488111715312,0.289,log10_fold_induction,1.60205999132796,0.10464335145935999,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,0.7185029191991423,20,kinase
BSK_BE3C_HLADR_down,"Data from the assay component BSK_BE3C_HLADR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_HLADR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene HLA-DRA. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""MHC Class II"".",NP_061984.2, , , ,,,Active,0.6325107277476646,7.988138092285526,10,1,0.025097172292079997,0.632,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7719568797095553,20,cell adhesion molecules
BSK_BE3C_IL1a_down,"Data from the assay component BSK_BE3C_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3, , , ,,,Active,0.661035933686976,8.281725471778179,10,1,0.026606208087899996,0.661,log10_fold_induction,1.60205999132796,0.07981862426369998,"[""Hit-call potentially confounded by overfitting""]",1,1,0.9477433566598062,20,cytokine
BSK_BE3C_IP10_down,"Data from the assay component BSK_BE3C_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,1.0020841623942474,11.972377298777422,10,1,0.027899893713299997,1.002,log10_fold_induction,1.60205999132796,0.08369968113989999,"[""Hit-call potentially confounded by overfitting""]",1,1,0.8215716414125733,20,cytokine
BSK_BE3C_MIG_down,"Data from the assay component BSK_BE3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,1.080041370976562,13.64011587196991,10,1,0.0077791965661199985,1.08,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.9293819537611206,20,cytokine
BSK_BE3C_MMP1_down,"Data from the assay component BSK_BE3C_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1, , , ,,,Active,0.39719999968049324,4.31660084177419,39.99999999999999,1.6020599913279623,0.030672282369078,0.331,log10_fold_induction,1.60205999132796,0.092016847107234,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.3952707139575093,20,protease
BSK_BE3C_PAI1_down,"Data from the assay component BSK_BE3C_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1, , , ,,,Active,0.4970083356369997,4.442763389371944,10,1,0.0372897295428,0.497,log10_fold_induction,1.60205999132796,0.11186918862840001,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1,1,0.9049511586693206,20,cytokine
BSK_BE3C_SRB_down,"Data from the assay component BSK_BE3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_BE3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.9340083563785233,11.795827964323133,10,1,0.005817857605706999,0.934,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.8636096226728536,20,cell cycle
BSK_BE3C_TGFb1_down,"Data from the assay component BSK_BE3C_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",P01137.2, , , ,,,Active,0.741599993004013,6.994895239825675,39.99999999999999,1.6020599913279623,0.0353400571692,0.618,log10_fold_induction,1.60205999132796,0.10602017150760001,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.3953141642352307,20,growth factor
BSK_BE3C_tPA_down,"Data from the assay component BSK_BE3C_tPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_tPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAT. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_000921.1, , , ,,,Active,0.25313934709578745,1.894487418190457,39.99999999999999,1.6020599913279623,0.04453963724175,0.253,log10_fold_induction,1.60205999132796,0.13361891172525,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,0.8163666444143816,20,protease
BSK_BE3C_uPA_down,"Data from the assay component BSK_BE3C_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1, , , ,,,Active,0.12101313966600938,1.4739141449220732,39.99999999999999,1.6020599913279623,0.02736774958092,0.121,log10_fold_induction,1.60205999132796,0.08210324874276,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.9720003859410474,20,protease
BSK_BE3C_uPAR_down,"Data from the assay component BSK_BE3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_BE3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.4911955797146426,4.3190116305944555,10,1,0.0379095667965,0.491,log10_fold_induction,1.60205999132796,0.11372870038949999,"[""Less than 50% efficacy"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Noisy data""]",1,1,0.8508564134792386,20,cytokine
BSK_CASM3C_IL8_down,"Data from the assay component BSK_CASM3C_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.22559999749362997,2.8491594759438272,39.99999999999999,1.6020599913279623,0.016910900838509997,0.188,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.3953766661301745,20,cytokine
BSK_CASM3C_MCP1_down,"Data from the assay component BSK_CASM3C_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.26519999804065264,3.0415594569423687,39.99999999999999,1.6020599913279623,0.029064037905,0.221,log10_fold_induction,1.60205999132796,0.08719211371499999,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.2750570935349461,20,cytokine
BSK_CASM3C_MCSF_down,"Data from the assay component BSK_CASM3C_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.6167999914850312,6.380989300332085,39.99999999999999,1.6020599913279623,0.03222070865265,0.514,log10_fold_induction,1.60205999132796,0.09666212595794998,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1.6020599913279623,1.6020599913279623,1.395022455178845,20,cytokine
BSK_CASM3C_MIG_down,"Data from the assay component BSK_CASM3C_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,0.3395999963886145,4.288894319550828,39.99999999999999,1.6020599913279623,0.015950413476900002,0.283,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.3945632027693402,20,cytokine
BSK_CASM3C_Proliferation_down,"Data from the assay component BSK_CASM3C_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.0439999997670653,10.735636653754938,39.99999999999999,1.6020599913279623,0.032415404055299996,0.87,log10_fold_induction,1.60205999132796,0.09724621216589999,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.0942443881969337,20,cell cycle
BSK_CASM3C_SAA_down,"Data from the assay component BSK_CASM3C_SAA was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_SAA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SAA1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""apolipoproteins"".",NP_954630.1, , , ,,,Active,0.34559999633451755,3.4059609595249727,39.99999999999999,1.6020599913279623,0.033823053213809996,0.288,log10_fold_induction,1.60205999132796,0.10146915964143,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.3950031784808856,20,cell adhesion molecules
BSK_CASM3C_SRB_down,"Data from the assay component BSK_CASM3C_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_CASM3C_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.7163999986267799,9.04759692965541,39.99999999999999,1.6020599913279623,0.015242156257229997,0.597,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.2043118502319785,20,cell cycle
BSK_CASM3C_Thrombomodulin_down,"Data from the assay component BSK_CASM3C_Thrombomodulin was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_Thrombomodulin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene THBD. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000352.1, , , ,,,Active,0.2663999909056876,2.6564406249648553,39.99999999999999,1.6020599913279623,0.0334281881304,0.222,log10_fold_induction,1.60205999132796,0.10028456439120001,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,1.3949714476949913,20,gpcr
BSK_CASM3C_uPAR_down,"Data from the assay component BSK_CASM3C_uPAR was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_uPAR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAUR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator"".",NP_002650.1, , , ,,,Active,0.4295999697291383,4.015353839887156,39.99999999999999,1.6020599913279623,0.0356631060723,0.358,log10_fold_induction,1.60205999132796,0.1069893182169,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279623,1.6020599913279623,1.3954201781367492,20,cytokine
BSK_CASM3C_VCAM1_down,"Data from the assay component BSK_CASM3C_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_CASM3C_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.192017313240383,2.2263344210854012,39.99999999999999,1.6020599913279623,0.028749396529979997,0.192,log10_fold_induction,1.60205999132796,0.08624818958993999,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.6020599913279623,1.6020599913279623,0.9766969854017022,20,cell adhesion molecules
BSK_hDFCGF_CollagenIII_down,"Data from the assay component BSK_hDFCGF_CollagenIII was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_CollagenIII_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene COL3A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""collagen"".",NP_000081.1, , , ,,,Active,0.8263996111410028,5.8384809280670025,10,1,0.047181200117099996,0.821,log10_fold_induction,1.60205999132796,0.14154360035129998,"[""Hit-call potentially confounded by overfitting""]",1,1,0.5794233626982541,20,cell adhesion molecules
BSK_hDFCGF_EGFR_down,"Data from the assay component BSK_hDFCGF_EGFR was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_EGFR_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene EGFR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""kinase"" intended target family, where the subfamily is ""receptor tyrosine kinase"".",NP_005219.2, , , ,"[148,148]",,Active,0.14701390161314637,1.1960693774351265,40.000000000000014,1.6020599913279625,0.0409713974754,0.147,log10_fold_induction,1.60205999132796,0.1229141924262,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,0.8994676588225051,20,kinase
BSK_hDFCGF_IL8_down,"Data from the assay component BSK_hDFCGF_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,1.7399999997916065,21.974900454901352,10,1,0.008495260327134,1.45,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.8053021668062128,20,cytokine
BSK_hDFCGF_IP10_down,"Data from the assay component BSK_hDFCGF_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,1.1850018571315246,14.650276176136034,10,1,0.0269619913164,1.185,log10_fold_induction,1.60205999132796,0.0808859739492,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7145311740214244,20,cytokine
BSK_hDFCGF_MCSF_down,"Data from the assay component BSK_hDFCGF_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.848047484077981,7.9310121363367605,10,1,0.0356426758443,0.848,log10_fold_induction,1.60205999132796,0.10692802753289998,"[""Hit-call potentially confounded by overfitting""]",1,1,0.6463883346978769,20,cytokine
BSK_hDFCGF_MIG_down,"Data from the assay component BSK_hDFCGF_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,1.4231999999857106,17.973953063705316,10,1,0.015977820005069997,1.186,log10_fold_induction,1,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7881197491676142,20,cytokine
BSK_hDFCGF_MMP1_down,"Data from the assay component BSK_hDFCGF_MMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_MMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",NP_002412.1, , , ,,,Active,0.618644755166145,7.781872786249428,10,1,0.026499394689809996,0.615,log10_fold_induction,1.60205999132796,0.07949818406942999,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7204300721061175,20,protease
BSK_hDFCGF_PAI1_down,"Data from the assay component BSK_hDFCGF_PAI1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_PAI1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SERPINE1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""plasmogen activator inhibitor"".",NP_000593.1, , , ,,,Active,0.5625806987639083,3.3964508007100274,10,1,0.055212605920499994,0.556,log10_fold_induction,1.60205999132796,0.1656378177615,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1,1,0.740117421548381,20,cytokine
BSK_hDFCGF_Proliferation_down,"Data from the assay component BSK_hDFCGF_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.289999999753961,9.520043580054121,10,1,0.0451678604517,1.075,log10_fold_induction,1,0.1355035813551,"[""Cell viability assay fit with gnls winning model"",""Hit-call potentially confounded by overfitting""]",1,1,0.792571499062551,20,cell cycle
BSK_hDFCGF_SRB_down,"Data from the assay component BSK_hDFCGF_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_hDFCGF_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.7279325724066809,9.193244723237296,10,1,0.024374730148650003,0.719,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.6987063207788093,20,cell cycle
BSK_hDFCGF_TIMP1_down,"Data from the assay component BSK_hDFCGF_TIMP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_TIMP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",NP_003245.1, , , ,,,Active,0.4323209392837667,3.2218878553381267,10,1,0.0447274971171,0.431,log10_fold_induction,1.60205999132796,0.1341824913513,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1,1,0.7566580480666752,20,protease inhibitor
BSK_hDFCGF_VCAM1_down,"Data from the assay component BSK_hDFCGF_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_hDFCGF_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,0.8010005106478849,5.668814527335183,10,1,0.04709982465089999,0.801,log10_fold_induction,1.60205999132796,0.14129947395269998,"[""Hit-call potentially confounded by overfitting""]",1,1,0.6615458992955843,20,cell adhesion molecules
BSK_KF3CT_ICAM1_down,"Data from the assay component BSK_KF3CT_ICAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_ICAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene ICAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_000192.2, , , ,,,Active,0.7102519822188078,8.969952074151694,10,1,0.02073805097175,0.71,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7796870250216329,20,cell adhesion molecules
BSK_KF3CT_IL1a_down,"Data from the assay component BSK_KF3CT_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3, , , ,,,Active,0.8386381908647349,9.769279259158832,10,1,0.0286148093637,0.879,log10_fold_induction,1,0.08584442809109999,"[""Hit-call potentially confounded by overfitting""]",1,1,0.6784708923469456,20,cytokine
BSK_KF3CT_IP10_down,"Data from the assay component BSK_KF3CT_IP10 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_IP10_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL10. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_001556.2, , , ,,,Active,1.5287999999362507,19.307602194296482,10,1,0.0138351257877,1.274,log10_fold_induction,1,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7917767173535764,20,cytokine
BSK_KF3CT_MCP1_down,"Data from the assay component BSK_KF3CT_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.5652187502908401,4.919038171682605,10,1,0.0383014409568,0.562,log10_fold_induction,1.60205999132796,0.1149043228704,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1,1,0.7219673056320427,20,cytokine
BSK_KF3CT_MMP9_down,"Data from the assay component BSK_KF3CT_MMP9 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_MMP9_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene MMP9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""matrix metalloproteinase"".",AAM97934.1, , , ,,,Active,1.0612474105599163,12.67868070945841,10,1,0.027901099882530003,1.025,log10_fold_induction,1,0.08370329964759,"[""Hit-call potentially confounded by overfitting""]",1,1,0.6978103599936888,20,protease
BSK_KF3CT_SRB_down,"Data from the assay component BSK_KF3CT_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_KF3CT_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.6539327902731163,8.258682742625673,10,1,0.00501083847705,0.633,log10_fold_induction,1,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Cell viability assay fit with gnls winning model""]",1,1,0.6624858380918057,20,cell cycle
BSK_KF3CT_TGFb1_down,"Data from the assay component BSK_KF3CT_TGFb1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TGFb1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TGFB1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""growth factor"" intended target family, where the subfamily is ""transforming growth factor beta"".",P01137.2, , , ,,,Active,0.6299999898262196,5.900945666237085,10,1,0.0355875157113,0.525,log10_fold_induction,1,0.10676254713389999,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1,1,0.7934949664873787,20,growth factor
BSK_KF3CT_TIMP2_down,"Data from the assay component BSK_KF3CT_TIMP2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_TIMP2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TIMP2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease inhibitor"" intended target family, where the subfamily is ""metalloproteinase inhibitor"".",, , , ,,,Active,1.037999999721912,11.291021527211855,10,1,0.030643817220029995,0.865,log10_fold_induction,1,0.09193145166008998,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7891409353576837,20,protease inhibitor
BSK_KF3CT_uPA_down,"Data from the assay component BSK_KF3CT_uPA was analyzed into 2 assay endpoints. This assay endpoint, BSK_KF3CT_uPA_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PLAU. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""protease"" intended target family, where the subfamily is ""serine protease"".",NP_002649.1, , , ,,,Active,1.0523999999507634,13.291026000244814,10,1,0.020151273081261,0.877,log10_fold_induction,1,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7921835023257047,20,protease
BSK_LPS_CD40_down,"Data from the assay component BSK_LPS_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.7612576199561969,5.515214438024729,40.000000000000014,1.6020599913279625,0.0460095510042,0.761,log10_fold_induction,1.60205999132796,0.13802865301259998,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.048745877612257,20,cytokine
BSK_LPS_Eselectin_down,"Data from the assay component BSK_LPS_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,1.1963999653363295,15.109638014748288,40.000000000000014,1.6020599913279625,0.0245760564798,0.997,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.393551618091504,20,cell adhesion molecules
BSK_LPS_IL1a_down,"Data from the assay component BSK_LPS_IL1a was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL1a_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene IL1A. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000566.3, , , ,,,Active,0.6730368932109438,5.4535417594673765,40.000000000000014,1.6020599913279625,0.041137602124499996,0.673,log10_fold_induction,1.60205999132796,0.1234128063735,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,0.9742605390095287,20,cytokine
BSK_LPS_IL8_down,"Data from the assay component BSK_LPS_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.8678090276307897,9.777429906496922,40.000000000000014,1.6020599913279625,0.029585451252860995,0.867,log10_fold_induction,1.60205999132796,0.08875635375858298,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.1039634938078862,20,cytokine
BSK_LPS_MCP1_down,"Data from the assay component BSK_LPS_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,1.1385848302863568,12.697057122621242,40.000000000000014,1.6020599913279625,0.029891042711459998,1.138,log10_fold_induction,1.60205999132796,0.08967312813438,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.071428814731511,20,cytokine
BSK_LPS_MCSF_down,"Data from the assay component BSK_LPS_MCSF was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_MCSF_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CSF1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""colony stimulating factor"".",NP_000748.3, , , ,,,Active,0.8021302175201195,7.696949144551918,40.000000000000014,1.6020599913279625,0.0347380155633,0.802,log10_fold_induction,1.60205999132796,0.1042140466899,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0090320089938751,20,cytokine
BSK_LPS_PGE2_down,"Data from the assay component BSK_LPS_PGE2 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_PGE2_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene PTGER2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""gpcr"" intended target family, where the subfamily is ""rhodopsin-like receptor"".",NP_000947.2, , , ,,,Active,0.32279999999400744,2.2898583170418676,40.000000000000014,1.6020599913279625,0.04698980683529999,0.269,log10_fold_induction,1.60205999132796,0.14096942050589997,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,0.4243559498850541,20,gpcr
BSK_LPS_SRB_down,"Data from the assay component BSK_LPS_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_LPS_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.2875999992382867,16.261426328954702,40.000000000000014,1.6020599913279625,0.018219059086199998,1.073,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.0844060166268958,20,cell cycle
BSK_LPS_TissueFactor_down,"Data from the assay component BSK_LPS_TissueFactor was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TissueFactor_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene F3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""coagulation factor"".",NP_001984.1, , , ,,,Active,0.6215999998796974,5.128496562292954,1,0,0.0404017039776,0.518,log10_fold_induction,1.60205999132796,0.1212051119328,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0,0,0.962549269552363,20,cytokine
BSK_LPS_TNFa_down,"Data from the assay component BSK_LPS_TNFa was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_TNFa_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene TNF. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_000585.2, , , ,,,Active,1.4207880788385592,10.434565878783706,40.000000000000014,1.6020599913279625,0.04538722854225,1.42,log10_fold_induction,1.60205999132796,0.13616168562675,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0759242767924917,20,cytokine
BSK_LPS_VCAM1_down,"Data from the assay component BSK_LPS_VCAM1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_LPS_VCAM1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene VCAM1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""Immunoglobulin CAM"".",NP_001069.1, , , ,,,Active,1.002188531027259,12.656892648853704,40.000000000000014,1.6020599913279625,0.0224178208338,1.002,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.0164608948625684,20,cell adhesion molecules
BSK_SAg_CD38_down,"Data from the assay component BSK_SAg_CD38 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD38_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD38. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""other cytokine"".",NP_001766.2, , , ,,,Active,0.8522334589324614,10.763072084264397,40.000000000000014,1.6020599913279625,0.0243080164845,0.852,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0374491397544758,20,cytokine
BSK_SAg_CD40_down,"Data from the assay component BSK_SAg_CD40 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD40_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD40. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001241.1, , , ,,,Active,0.9353366066856834,9.381648187016271,40.000000000000014,1.6020599913279625,0.0332328459435,0.935,log10_fold_induction,1.60205999132796,0.09969853783049999,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.0523699310798493,20,cytokine
BSK_SAg_CD69_down,"Data from the assay component BSK_SAg_CD69 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_CD69_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CD69. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""inflammatory factor"".",NP_001772.1, , , ,,,Active,0.5831113792080981,5.507334214653796,40.000000000000014,1.6020599913279625,0.03529302057225,0.583,log10_fold_induction,1.60205999132796,0.10587906171674999,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.6020599913279625,1.6020599913279625,1.0209151259277478,20,cytokine
BSK_SAg_Eselectin_down,"Data from the assay component BSK_SAg_Eselectin was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_Eselectin_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene SELE. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell adhesion molecules"" intended target family, where the subfamily is ""selectins"".",NP_000441.2, , , ,,,Active,1.0583999999735605,9.22300981609619,10,1,0.038252154885,0.882,log10_fold_induction,1.60205999132796,0.114756464655,"[""Hit-call potentially confounded by overfitting""]",1,1,0.9742327219886989,20,cell adhesion molecules
BSK_SAg_IL8_down,"Data from the assay component BSK_SAg_IL8 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_IL8_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL8. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""interleukins"".",NP_000575.1, , , ,,,Active,0.7180471980699702,4.780110195139081,40.000000000000014,1.6020599913279625,0.050071872038999994,0.676,log10_fold_induction,1.60205999132796,0.150215616117,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,0.9796794963870175,20,cytokine
BSK_SAg_MCP1_down,"Data from the assay component BSK_SAg_MCP1 was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MCP1_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CCL2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002973.1, , , ,,,Active,0.813798606183749,8.548730688974672,40.000000000000014,1.6020599913279625,0.031731751991099996,0.803,log10_fold_induction,1.60205999132796,0.09519525597329999,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.6020599913279625,1.6020599913279625,1.2466299557636462,20,cytokine
BSK_SAg_MIG_down,"Data from the assay component BSK_SAg_MIG was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_MIG_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the signaling as they relate to the gene CXCL9. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cytokine"" intended target family, where the subfamily is ""chemotactic factor"".",NP_002407.1, , , ,,,Active,1.3651326024371804,17.240605201086375,40.000000000000014,1.6020599913279625,0.00921114872622,1.362,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.6020599913279625,1.6020599913279625,1.1529843381996827,20,cytokine
BSK_SAg_PBMCCytotoxicity_down,"Data from the assay component BSK_SAg_PBMCCytotoxicity was analyzed into 2 assay endpoints. This assay endpoint, BSK_SAg_PBMCCytotoxicity_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the signaling. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""proliferation"".",, , , ,,,Active,0.5972108233670609,7.542326664168166,10,1,0.0217234984974,0.576,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy""]",1,1,0.7981958953173474,20,cell cycle
BSK_SAg_Proliferation_down,"Data from the assay component BSK_SAg_Proliferation was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_Proliferation_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,0.907165688453931,7.579943040767543,10,1,0.0398932500141,0.898,log10_fold_induction,1.60205999132796,0.1196797500423,"[""Hit-call potentially confounded by overfitting""]",1,1,0.7615527189495976,20,cell cycle
BSK_SAg_SRB_down,"Data from the assay component BSK_SAg_SRB was analyzed into 2 assay endpoints. 
This assay endpoint, BSK_SAg_SRB_down, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of viability reporter, measures of total protein for loss-of-signal activity can be used to understand the viability at the cellular-level. 
Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cell cycle"" intended target family, where the subfamily is ""cytotoxicity"".",, , , ,,,Active,1.3355999974196706,16.86763045653958,10,1,0.017346765986949,1.113,log10_fold_induction,1.60205999132796,0.07918124604762482,"[""Hit-call potentially confounded by overfitting""]",1,1,1.057835094348834,20,cell cycle
CCTE_GLTED_hDIO1_dn,"Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",, , , ,,,Active,82.0208168738096,4.1010408436904795,70.41031737764786,1.847636301924426,5.074688733372146,69.4045801526717,percent_activity,2.30102999566398,20,,1.5532232631135972,1.462943651613869,1.2760449329867418,20,deiodinase
CCTE_GLTED_hDIO1_dn,"Data from the assay component CCTE_GLTED_hDIO1 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO1_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 1'.",, , , ,,,Active,82.0208168738096,4.1010408436904795,70.41031737764786,1.847636301924426,5.074688733372146,69.4045801526717,percent_activity,2.30102999566398,20,,1.5532232631135972,1.462943651613869,1.2760449329867418,20,deiodinase
CCTE_GLTED_hDIO2_dn,"Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.",, , , ,,,Active,87.38418288256405,4.369209144128202,85.25785408527655,1.9307343973862776,4.347339401816814,78.26843594,percent_activity,2.30102999566398,20,,1.706211076189143,1.6090168153640736,1.5245953690442362,20,deiodinase
CCTE_GLTED_hDIO2_dn,"Data from the assay component CCTE_GLTED_hDIO2 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO2_dn, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 2'.",, , , ,,,Active,87.38418288256405,4.369209144128202,85.25785408527655,1.9307343973862776,4.347339401816814,78.26843594,percent_activity,2.30102999566398,20,,1.706211076189143,1.6090168153640736,1.5245953690442362,20,deiodinase
CCTE_GLTED_hDIO3_dn,"Data from the assay component CCTE_GLTED_hDIO3 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO3_dn, was analyzed in the down fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.",, , , ,,,Active,97.07709836128208,4.853854918064104,15.881142485730075,1.2008817422598703,4.524033444680399,97.56389776,% inhibition,2,20,,0.9981130286325129,0.9277992288163586,0.8706341606300032,20,deiodinase
CCTE_GLTED_hDIO3_dn,"Data from the assay component CCTE_GLTED_hDIO3 was analyzed into 1 assay endpoint. This assay endpoint, CCTE_GLTED_hDIO3_dn, was analyzed in the down fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene DIO3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'deiodinase' intended target family, where the subfamily is 'deiodinase Type 3'.",, , , ,,,Active,97.07709836128208,4.853854918064104,15.881142485730075,1.2008817422598703,4.524033444680399,97.56389776,% inhibition,2,20,,0.9981130286325129,0.9277992288163586,0.8706341606300032,20,deiodinase
CCTE_GLTED_hIYD_dn,"Data from the assay component CCTE_GLTED_hIYD was analyzed at the assay endpoint CCTE_GLTED_hIYD_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.",, , , ,,,Active,85.95897881537773,4.297948940768887,173.2123856859417,2.2385789433553374,6.805901797768499,46.07789358,percent_activity,2.30102999566398,20,,1.8574762303026318,1.8661065599055886,1.5368545430947653,19.993499755859375,dehalogenase
CCTE_GLTED_hIYD_dn,"Data from the assay component CCTE_GLTED_hIYD was analyzed at the assay endpoint CCTE_GLTED_hIYD_dn in the positive analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, loss-of-signal activity can be used to understand iodotyrosine deiodinase activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the 'dehalogenase' intended target family, where the subfamily is 'iodotyrosine deiodinase'.",, , , ,,,Active,85.95897881537773,4.297948940768887,173.2123856859417,2.2385789433553374,6.805901797768499,46.07789358,percent_activity,2.30102999566398,20,,1.8574762303026318,1.8661065599055886,1.5368545430947653,19.993499755859375,dehalogenase
CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr,"The assay component endpoint CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion to understand changes in cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,58.1249999364025,2.906249996820125,69.7287373442063,1.84341180102295,3.1322638158,40.466015,percent activity,2,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64691562102538,1.34210653313498,1.17418093412363,20,cell cycle
CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr,"The assay component endpoint CCTE_Harrill_HTTr_Viability_MCF7_DMEM_6hr was analyzed in the positive fitting direction relation to DMSO as the negative control and baseline of activity. Using a type of viability reporter, gain-of-signal activity can be used to evaluate membrane integrity using propidium iodide dye exclusion to understand changes in cytotoxicity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,58.1249999364025,2.906249996820125,69.7287373442063,1.84341180102295,3.1322638158,40.466015,percent activity,2,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64691562102538,1.34210653313498,1.17418093412363,20,cell cycle
CCTE_Padilla_ZF_144hpf_TERATOSCORE_up,"Data from the assay component CCTE_Padilla_ZF_144hpf_TERATOSCORE was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Padilla_ZF_144hpf_TERATOSCORE_up, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of morphological reporter, gain-of-signal activity can be used to understand changes in  developmental defect  as they relate to the whole embryo. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""malformation"" intended target family, where the subfamily is ""total"".",, , , ,,,Active,98.2294152773118,4.91147076386559,10.209398601847314,1.00900016014845,1.53481347591287,98.8776381096667,percent_activity,1.47712125471966,20,,0.934957576091385,0.845473141979214,0.889719728871829,20,malformation
CCTE_Shafer_MEA_acute_AB_dn,"Data from the assay component CCTE_Shafer_MEA_acute_AB was analyzed into 1 assay endpoint. This assay endpoint, CCTE_Shafer_MEA_acute_AB_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand cell viability.",, , , ,,,Active,65.60623232397077,1.6349812894403035,19.7938272631018,1.2965297759416659,13.375531725795158,43.044392945778476,percent_activity,1.60205999132796,40.126595177385475,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Borderline active""]",1.5945660000996906,1.5945660000996906,-0.14536929693877032,20,cell cycle
CCTE_Shafer_MEA_acute_burst_number_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.81981478024568,1.4620594695436904,1.7529985441990903,0.24378155542832752,27.317588027077427,99.76789589167151,percent_activity,1.60205999132796,81.95276408123229,,1.0136546962848823,1.0136546962848823,-1.947214634366746,20,neuroactivity
CCTE_Shafer_MEA_acute_burst_percentage_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_percentage_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_percentage_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,83.57781853244063,5.71057575466229,4.04032956350621,0.6064167912924552,4.878540105417866,80.79064317353345,percent_activity,1.60205999132796,14.635620316253597,"[""Noisy data""]",0.2941383257786524,0.2941383257786524,0.16368777498062825,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_area_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_area was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_area_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.95363888790705,1.2906053265929922,2.0418758743760868,0.31002933779398617,30.9812345200235,99.90515277703676,percent_activity,1.60205999132796,92.9437035600705,"[""Borderline active"",""Only one conc above baseline, active""]",1.3501568974228533,1.3501568974228533,-1.5393102102340543,20,neuroactivity
CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn,"Data from the assay component CCTE_Shafer_MEA_acute_cross_correlation_HWHM was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_cross_correlation_HWHM_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,107.88344659584291,3.532417754929763,9.86007707199079,0.9938803096480562,10.180321626765236,82.57686676427521,percent_activity,1.60205999132796,30.54096488029571,,0.5390131678836417,0.5390131678836417,-0.0817468023642356,20,neuroactivity
CCTE_Shafer_MEA_acute_firing_rate_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_firing_rate_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_firing_rate_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.75252081412012,1.687364791322112,1.8845788836301907,0.27521432061730494,23.65671438880932,99.32527891627386,percent_activity,1.60205999132796,70.97014316642796,,0.6624299004664993,0.6624299004664993,-1.9942494693925445,20,neuroactivity
CCTE_Shafer_MEA_acute_network_burst_percentage_dn,"Data from the assay component CCTE_Shafer_MEA_acute_network_burst_percentage was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_network_burst_percentage_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,106.66563727356551,20.05541713686081,53.97914178699242,1.7322259754384233,1.772848312348149,45.98338875098368,percent_activity,1,5.3185449370444475,"[""Noisy data""]",0.9803985553139349,0.9803985553139349,1.1717452430632287,20,neuroactivity
CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_per_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_burst_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,66.3722887258368,2.129012919411314,30.795369151127133,1.4884854144446722,10.391715353264766,37.040165933463555,percent_activity,1.60205999132796,31.1751460597943,"[""Borderline active"",""Only one conc above baseline, active""]",1.4379759863790025,1.4379759863790025,0.5738888526377875,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_electrodes_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,41.907823675773336,1.9903002494191502,11.070484100660716,1.0441666125362414,7.018676987388164,39.1235051786954,percent_activity,1.60205999132796,21.056030962164492,"[""Only one conc above baseline, active""]",1.0446964496749234,1.0446964496749234,0.9247289098611475,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_dn,"Data from the assay component CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_per_network_burst_spike_number_mean_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,85.75328483218087,1.3783977670929315,9.511865545399184,0.9782657027014778,20.73743077637071,69.92268563738975,percent_activity,1.60205999132796,62.21229232911213,"[""Only one conc above baseline, active"",""Borderline active""]",1.4006348905852808,1.4006348905852808,0.023304765906848823,20,neuroactivity
CCTE_Shafer_MEA_acute_per_network_burst_spike_number_std_dn,"Data from the assay component CCTE_Shafer_MEA_acute_burst_spike_number_std was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_burst_spike_number_std_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,94.74174610411757,1.8180580998732578,6.523970517280515,0.8145119897362155,17.37050209611422,94.84487435180824,percent_activity,1.60205999132796,52.11150628834265,"[""Only one conc above baseline, active""]",0.8373553498189482,0.8373553498189482,0.5645791504218535,20,neuroactivity
CCTE_Shafer_MEA_acute_spike_number_dn,"Data from the assay component CCTE_Shafer_MEA_acute_spike_number was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_spike_number_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,119.74961411591133,1.7259089929824152,1.8265745462959584,0.26163740136826164,23.12783478209955,99.33262479263517,percent_activity,1.60205999132796,69.38350434629865,,0.5959841453981212,0.5959841453981212,-2.031727090286263,20,neuroactivity
CCTE_Shafer_MEA_acute_synchrony_index_dn,"Data from the assay component CCTE_Shafer_MEA_acute_synchrony_index was analyzed into 2 assay endpoints. This assay endpoint, CCTE_Shafer_MEA_acute_synchrony_index_dn, was analyzed in the negative analysis fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of functional reporter, loss-of-signal activity can be used to understand electrical activity.",, , , ,,,Active,56.04898925252499,5.420804208712912,6.605702656327092,0.8199190208203195,3.446535919426672,51.887626881297464,percent_activity,1.60205999132796,10.339607758280016,"[""Noisy data""]",0.4180870334839852,0.4180870334839852,0.22589206032217257,20,neuroactivity
CCTE_Simmons_AUR_TPO_dn,"Data from the assay component CCTE_Simmons_AUR_TPO was analyzed at the endpoint, CCTE_Simmons_AUR_TPO_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of enzyme reporter, the Amplex UltraRed assay, loss-of-signal activity can be used to understand decreased peroxidase activity in the presence of excess hydrogen peroxidase. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the oxidoreductase intended target family, where the subfamily is peroxidase.",P14650.1, , , ,,,Active,48.8642734256526,2.44321367128263,68.33758443514567,1.83465962349658,5.55295187687267,28.5728425610888,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.74450409613125,1.67266902662787,1.29471175281621,20,oxidoreductase
CCTE_Simmons_CellTiterGLO_HEK293T,"Data from the assay component CCTE_Simmons_CellTiterGLO_HEK293T was analyzed at the endpoint, CCTE_Simmons_CellTiterGLO_HEK293T_dn, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. This assay was run in parallel with aeid 1508 as a means of indicating the range of chemical cytotoxicity or reactivity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,98.223769002347,4.91118845011735,7.0754913114694,0.849756601998689,5.60777764752233,98.2522175920449,percent_activity,2,20,,0.558056447588491,0.512548374018798,0.379811339134017,20,cell cycle
CLD_CYP1A1_24hr,"Data from the assay component CLD_CYP1A1_24hr was analyzed at the endpoint, CLD_CYP1A1_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000490.1, , , ,,,Active,2.12361566175703,2.12361566175703,28.803400015202463,1.45944375583862,0.653028314193223,1.96831896950129,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.45299132013222,1.59658075067461,1.33780294218783,20,cyp
CLD_CYP1A1_48hr,"Data from the assay component CLD_CYP1A1_48hr was analyzed at the endpoint, CLD_CYP1A1_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP1A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000490.1, , , ,,,Active,2.30750211675223,2.30750211675223,5.812573981599216,0.764368493570411,0.615334596430808,2.3691868942795,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.745207362271774,0.863440633282694,0.607343510274439,20,cyp
CLD_CYP2B6_24hr,"Data from the assay component CLD_CYP2B6_24hr was analyzed at the endpoint, CLD_CYP2B6_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,3.96942942348623,3.96942942348623,4.105590090008865,0.613375586404777,0.415288000995156,3.95211412762419,log2_fold_induction,1.60205999132796,1,,0.552493971222238,0.569625497379843,0.490466462502912,20,cyp
CLD_CYP2B6_48hr,"Data from the assay component CLD_CYP2B6_48hr was analyzed at the endpoint, CLD_CYP2B6_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,2.91834162457038,2.91834162457038,4.4673002991644175,0.650045147431871,0.450385337247368,2.8748891226753,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.612144479058775,0.641416143244214,0.522215130926236,20,cyp
CLD_CYP2B6_6hr,"Data from the assay component CLD_CYP2B6_6hr was analyzed at the endpoint, CLD_CYP2B6_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2B6. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000758.1, , , ,,,Active,2.65667790786084,2.65667790786084,3.936928246187742,0.59515749948195,0.396566308888419,2.67647722742531,log2_fold_induction,1.60205999132796,1,,0.566340427467808,0.583198017903949,0.469730041791511,20,cyp
CLD_CYP2C9_48hr,"Data from the assay component CLD_CYP2C9_48hr was analyzed at the endpoint, CLD_CYP2C9_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP2C9. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_000762.2, , , ,,,Active,1.10847788153057,1.10847788153057,4.148156831508914,0.617855167623305,0.349259404300352,1.09226818471725,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",0.764915384104921,0.806445889318371,0.472382893568463,20,cyp
CLD_CYP3A4_24hr,"Data from the assay component CLD_CYP3A4_24hr was analyzed at the endpoint, CLD_CYP3A4_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,5.43123051919582,5.43123051919582,4.1208191777255845,0.614983558024002,0.719693813962598,5.42794035945192,log2_fold_induction,1.60205999132796,1,,0.529020469258116,0.590975422466629,0.488105684982062,20,cyp
CLD_CYP3A4_48hr,"Data from the assay component CLD_CYP3A4_48hr was analyzed at the endpoint, CLD_CYP3A4_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,6.14242840422453,6.14242840422453,10.80308079078832,1.03354762397231,0.783724870256564,5.06611214612854,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.422592218331747,0.855288810403457,0.213770284049293,20,cyp
CLD_CYP3A4_6hr,"Data from the assay component CLD_CYP3A4_6hr was analyzed at the endpoint, CLD_CYP3A4_6hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP3A4. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where subfamily is xenobiotic metabolism.",NP_059488.2, , , ,,,Active,2.54401408852527,2.54401408852527,3.891922366233769,0.590164168633171,0.56118133263598,2.57279642106601,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.564384334276325,0.629997086980378,0.459763693237406,20,cyp
CLD_SULT2A_24hr,"Data from the assay component CLD_SULT2A_24hr was analyzed at the endpoint, CLD_SULT2A_24hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.",NP_003158.2, , , ,,,Active,1.58248146675542,1.58248146675542,5.340688760206892,0.727597269288503,0.429222510653292,1.55150528853668,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",0.761648638274472,0.820481473960442,0.589161873421497,20,transferase
CLD_SULT2A_48hr,"Data from the assay component CLD_SULT2A_48hr was analyzed at the endpoint, CLD_SULT2A_48hr, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene SULT2A1. Furthermore, this assay endpoint can be referred to as a primary readout. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the transferase intended target family, where subfamily is sulfotransferase.",NP_003158.2, , , ,,,Active,1.31347437198843,1.31347437198843,31.144161894100186,1.49337664827277,0.384258977273262,1.15391425200839,log2_fold_induction,1.60205999132796,1,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.55803890722611,1.60321004960854,1.37090001821441,20,transferase
CPHEA_Stoker_NIS_Cytotoxicity," Data from the assay component CPHEA_Stoker_NIS_Cytotoxicity was analyzed at the endpoint, CPHEA_Stoker_NIS_Cytotoxicity, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,109.22074545058265,2.230394035619156,44.36038857829066,1.64699534173024,16.323086669341674,90.18769205215513,percent_activity,2,48.96926000802502,"[""Only highest conc above baseline, active""]",1.6003550539870015,1.6003550539870015,1.1527254530116267,20,cell cycle
CPHEA_Stoker_NIS_Cytotoxicity," Data from the assay component CPHEA_Stoker_NIS_Cytotoxicity was analyzed at the endpoint, CPHEA_Stoker_NIS_Cytotoxicity, in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, measures of ATP content for loss-of-signal activity can be used to understand the viability. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,109.22074545058265,2.230394035619156,44.36038857829066,1.64699534173024,16.323086669341674,90.18769205215513,percent_activity,2,48.96926000802502,"[""Only highest conc above baseline, active""]",1.6003550539870015,1.6003550539870015,1.1527254530116267,20,cell cycle
CPHEA_Stoker_NIS_Inhibition_RAIU,enzyme reporter assay using MicroBeta radioactivity plate reader to monitor enzyme in HEK293T cell line: AEID2037,, , , ,,,Active,110.00441758927623,1.8281270804911331,29.020770570754706,1.4627089398103217,20.057762716678525,91.28441548407037,percent_activity,2,60.173288150035575,"[""Only highest conc above baseline, active""]",1.5328478444560298,1.5328478444560298,0.6455286960884274,20,transporter
CPHEA_Stoker_NIS_Inhibition_RAIU,enzyme reporter assay using MicroBeta radioactivity plate reader to monitor enzyme in HEK293T cell line: AEID2037,, , , ,,,Active,110.00441758927623,1.8281270804911331,29.020770570754706,1.4627089398103217,20.057762716678525,91.28441548407037,percent_activity,2,60.173288150035575,"[""Only highest conc above baseline, active""]",1.5328478444560298,1.5328478444560298,0.6455286960884274,20,transporter
LTEA_HepaRG_ABCB11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003733.2, , , ,"[27,27]",,Active,3.34113581755215,5.952996891580514,40.45638854454251,1.60698711162361,0.187084246719363,3.33874235838284,log2_fold_induction,2,0.561252740158089,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.52012671416257,1.52012671416257,1.48770420172893,20,transporter
LTEA_HepaRG_ABCG2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004818.2, , , ,,,Active,1.38498633435835,2.2982165939219903,41.19435784675577,1.61483773729969,0.200878417062049,1.13755377884044,log2_fold_induction,2,0.602635251186147,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54139132177026,1.54139132177026,0.996509988074576,20,transporter
LTEA_HepaRG_ACOX1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_009223.2, , , ,,,Active,1.22121148270031,3.0193884324681313,37.35651085288286,1.57236630577798,0.134818855982927,0.995104826898641,log2_fold_induction,2,0.404456567948781,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.36501875051549,1.36501875051549,0.924112785369191,20,oxidase
LTEA_HepaRG_ADK_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006712.2, , , ,,,Active,4.10090367542481,8.2338715944055,66.12915147558925,1.82039295016756,0.166017635341442,3.19554171909482,log2_fold_induction,2,0.498052906024326,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.53812519146099,1.53812519146099,1.50696375777351,20,kinase
LTEA_HepaRG_APOA5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_443200.2, , , ,,,Active,1.71607255929938,2.0063461859209912,1.9856376906806503,0.297900007858961,0.285107420866427,2.22726292236642,log2_fold_induction,1,0.855322262599281,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Borderline active""]",0.295280612265755,0.295280612265755,-0.611881648774044,20,apolipoprotein
LTEA_HepaRG_BAD_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_004313.1, , , ,,,Active,1.57348559206982,1.4846497649993124,38.34094098079489,1.58366276732535,0.353278739350926,1.57274866395647,log2_fold_induction,2,1.05983621805278,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.62299110702832,1.62299110702832,1.46436170319877,20,cell cycle
LTEA_HepaRG_BAX_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_620116.1, , , ,,,Active,1.88480156530869,3.744933378216862,82.77234629427393,1.91788526603869,0.167764583501183,1.53938458738256,log2_fold_induction,2,0.503293750503549,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.86239724261824,1.86239724261824,1.79714366937742,20,cell cycle
LTEA_HepaRG_BCL2L11_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_619527.1, , , ,,,Active,0.657114198650672,1.599229938535492,70.34203205877124,1.84721491017319,0.136964710914227,0.46935838974621,log2_fold_induction,2,0.410894132742681,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.93264856326581,1.93264856326581,1.48065896539089,20,cell cycle
LTEA_HepaRG_BCL2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000624.2, , , ,,,Active,4.00041790285635,8.42331746193765,83.38301417774704,1.92107759020384,0.15830729879421,3.24285436587615,log2_fold_induction,2,0.47492189638263,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81225248977597,1.81225248977597,1.80179689705531,20,cell cycle
LTEA_HepaRG_BID_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001187.1, , , ,,,Active,5.1413857751023,7.366472552496857,86.06463176053178,1.93482471490377,0.232648020630518,3.91916744362852,log2_fold_induction,2,0.697944061891554,"[""Noisy data"",""Noisy data""]",1.83128681367253,1.83128681367253,1.81192335224554,20,cell cycle
LTEA_HepaRG_CASP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_116786.1, , , ,,,Active,2.14739239138773,4.667720662261119,44.148577884098394,1.64491671862625,0.153350535644343,1.7378772241685,log2_fold_induction,2,0.460051606933029,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.32287524812001,1.32287524812001,1.10043106705663,20,protease
LTEA_HepaRG_CASP8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_203520.1, , , ,,,Active,2.30142202551901,5.347987491091075,58.263288784805724,1.7653949955814,0.143444739998166,1.91785168833564,log2_fold_induction,2,0.430334219994498,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54533415653209,1.54533415653209,1.43640351649971,20,protease
LTEA_HepaRG_CAT_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001743.1, , , ,,,Active,3.17799512755612,5.599589927748798,60.732446746034974,1.78342077802519,0.189180229776443,2.57152368598914,log2_fold_induction,2,0.567540689329329,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55435913141936,1.55435913141936,1.45359724379464,20,catalase
LTEA_HepaRG_CDKN1A_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000380.1, , , ,,,Active,1.90028515596728,4.8804770336107,92.1263846302696,1.96438402822414,0.129788211471984,1.25729406053412,log2_fold_induction,2,0.389364634415952,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.89077338846053,1.89077338846053,1.84510371440709,20,cell cycle
LTEA_HepaRG_CYP1A1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000490.1, , , ,"[57,57]",,Active,1.32747869347312,1.474025261969523,11.419510643434117,1.05764749362876,0.300193564683644,1.21492649630003,log2_fold_induction,1.47712125471966,0.900580694050932,"[""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting""]",1.09818919570504,1.09818919570504,0.938317472163125,20,cyp
LTEA_HepaRG_CYP1A2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000752.2, , , ,"[131,131]",,Active,4.4021245410591,4.636290527470042,109.93423732331732,2.04113296781001,0.316497604782422,2.45111725719464,log2_fold_induction,2,0.949492814347266,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.97103659611407,1.97103659611407,1.92182874121245,20,cyp
LTEA_HepaRG_CYP2B6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000758.1, , , ,,,Active,4.75260715558206,6.304395834798593,5.466383665235778,0.737700109948539,0.251285361310856,4.02606611065124,log2_fold_induction,1.47712125471966,0.753856083932568,"[""Noisy data"",""Noisy data""]",0.00126295367076923,0.00126295367076923,-0.232082943106791,20,cyp
LTEA_HepaRG_CYP2C19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000760.1, , , ,,,Active,4.63169358558447,8.258911530023731,89.28641316001286,1.95078537670973,0.186937207917646,3.30034110930305,log2_fold_induction,2,0.560811623752938,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84317641238247,1.84317641238247,1.83150503375734,20,cyp
LTEA_HepaRG_CYP2C19_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000760.1, , , ,,,Active,1.24564631386924,2.2211492435434996,10.393100103812742,1.01674511032524,0.186937207917646,1.11575230602844,log2_fold_induction,2,0.560811623752938,"[""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Noisy data"",""Only highest conc above baseline, active""]",1.00589887078678,1.00589887078678,0.897463186140541,20,cyp
LTEA_HepaRG_CYP2C8_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000761.3, , , ,,,Active,5.19164470634739,8.019235737159038,83.11074358786803,1.91965716793981,0.215799646271804,4.22946137764922,log2_fold_induction,2,0.647398938815412,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.81386899953298,1.81386899953298,1.80037466692653,20,cyp
LTEA_HepaRG_CYP2C9_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000762.2, , , ,,,Active,5.35486768512325,5.686410725744901,83.14558359600458,1.91983918595694,0.313898517206961,4.35961248520641,log2_fold_induction,2,0.941695551620883,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83598414137637,1.83598414137637,1.80055887079409,20,cyp
LTEA_HepaRG_CYP2E1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000764.1, , , ,,,Active,9.84828686376088,20.563211026548803,49.571266977725834,1.6952300190545,0.159642493756543,8.09389778714667,log2_fold_induction,2,0.478927481269629,,1.0941307325993,1.0941307325993,1.25107897099581,20,cyp
LTEA_HepaRG_CYP3A4_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_059488.2, , , ,,,Active,7.38440171148429,6.223260041799312,85.31152301889112,1.93100769524177,0.395526977922934,5.75971727954688,log2_fold_induction,2,1.1865809337688,"[""Noisy data"",""Only highest conc above baseline, active"",""Noisy data"",""Only highest conc above baseline, active""]",1.84086581575186,1.84086581575186,1.81119682545232,20,cyp
LTEA_HepaRG_CYP3A4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_059488.2, , , ,,,Active,4.28586761494087,3.6119471440756796,11.618207607206658,1.06513913267203,0.395526977922934,2.95276153815043,log2_fold_induction,2,1.1865809337688,"[""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Noisy data"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Noisy data"",""Borderline active""]",1.01289709666491,1.01289709666491,0.945580788063153,20,cyp
LTEA_HepaRG_CYP3A5_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000768.1, , , ,,,Active,2.99824070224859,3.9216788570871954,55.96603050508951,1.74792450485437,0.254843296413747,2.38048873390542,log2_fold_induction,2,0.764529889241241,,1.53829355041572,1.53829355041572,1.31831794265812,20,cyp
LTEA_HepaRG_CYP3A7_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000756.3, , , ,,,Active,4.36310600074392,5.621925821575798,85.22711605550572,1.93057779288504,0.258695812266514,3.41321824736404,log2_fold_induction,2,0.776087436799542,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84739696985559,1.84739696985559,1.8111855926223,20,cyp
LTEA_HepaRG_CYP4A11_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000769.2, , , ,,,Active,9.05035511486013,14.158515610810682,57.527271101678785,1.75987377305919,0.213072127136213,7.54196259588578,log2_fold_induction,2,0.639216381408639,,1.37061477222965,1.37061477222965,1.42798921644975,20,cyp
LTEA_HepaRG_CYP4A22_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001010969.2, , , ,,,Active,1.18796630492133,1.4707265104095792,15.867080872452725,1.20049703528692,0.269247045935707,0.835164565246986,log2_fold_induction,1.47712125471966,0.807741137807121,"[""Only highest conc above baseline, active"",""Borderline active"",""Only highest conc above baseline, active"",""Borderline active""]",1.49951829608811,1.49951829608811,0.328518219901355,20,cyp
LTEA_HepaRG_CYP7A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000771.2, , , ,,,Active,8.68644632984831,16.172216957975593,63.83361551744886,1.80504944343981,0.179040518530855,7.00426566538379,log2_fold_induction,2,0.537121555592565,,1.43219456637764,1.43219456637764,1.50379694656317,20,cyp
LTEA_HepaRG_DDIT3_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001181982.1, , , ,,,Active,5.82659464420299,10.136489418541968,83.47113492515552,1.92153631847766,0.191604621140491,4.7153491290436,log2_fold_induction,2,0.574813863421473,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.80143889425453,1.80143889425453,1.80225600005431,20,dna binding
LTEA_HepaRG_EGF_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001954.2, , , ,,,Active,1.50958313549402,2.6083267376692945,96.8997829665605,1.98632280433115,0.192918460417901,0.849851208421228,log2_fold_induction,2,0.578755381253703,"[""Borderline active"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.96052601905761,1.96052601905761,1.86704249051049,20,growth factor
LTEA_HepaRG_FABP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001434.1, , , ,,,Active,7.80316226607337,16.169204488094742,58.16040251961361,1.76462740354978,0.160864691309103,5.95134392226334,log2_fold_induction,2,0.482594073927309,,1.31731073126799,1.31731073126799,1.40318622881453,20,transporter
LTEA_HepaRG_FAS_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000034.1, , , ,,,Active,2.90319302289846,5.204405564695281,59.53422997298452,1.77476674075202,0.185944580145241,2.06787694455148,log2_fold_induction,2,0.557833740435723,,0.951386370637984,0.951386370637984,0.515028480360552,20,cytokine receptor
LTEA_HepaRG_FASN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_004095.4, , , ,"[58,34,34,58]",,Active,1.80419769112342,4.908904772759999,33.81905892240209,1.52916151838608,0.122511895873739,1.80388592280789,log2_fold_induction,2,0.367535687621217,,1.45515456888119,1.45515456888119,1.40988110284507,20,lyase
LTEA_HepaRG_FMO3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001002294.1, , , ,,,Active,4.93772313003678,11.325300657404977,42.87902608374417,1.63224491261617,0.145330155887393,4.93208602490425,log2_fold_induction,2,0.435990467662179,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.50550593089649,1.50550593089649,1.51296352281221,20,oxidoreductase
LTEA_HepaRG_FOXO1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002006.2, , , ,,,Active,1.89085540109713,4.651357191120692,66.86720380171957,1.8252131626066,0.135505640139235,1.52061803362947,log2_fold_induction,2,0.406516920417705,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.66491076070189,1.66491076070189,1.55324909201768,20,dna binding
LTEA_HepaRG_GADD45A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001915.1, , , ,,,Active,2.19642943775879,3.6269478687202126,29.06246738332498,1.46333248282758,0.201862053831487,1.61297396045621,log2_fold_induction,2,0.605586161494461,"[""Noisy data"",""Borderline active"",""Hit-call potentially confounded by overfitting"",""Noisy data"",""Borderline active"",""Hit-call potentially confounded by overfitting""]",0.654503097030152,0.654503097030152,-0.376735955966556,20,cell cycle
LTEA_HepaRG_GADD45G_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006696.1, , , ,,,Active,4.34879571074626,9.295738428605217,73.88920611511531,1.86858100041075,0.155942271975725,3.60004888144638,log2_fold_induction,2,0.467826815927175,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69150962084853,1.69150962084853,1.68469014886157,20,mutagenicity response
LTEA_HepaRG_GSTA2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000837.3, , , ,,,Active,10.2530801411182,15.585827903987923,83.7287556315363,1.92287463681473,0.219282119719688,8.2591056604388,log2_fold_induction,2,0.657846359159064,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.77738313849695,1.77738313849695,1.80359423075259,20,transferase
LTEA_HepaRG_GSTM3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000840.2, , , ,,,Active,3.3648493526521,4.317295741757709,93.82676846383569,1.9723267588229,0.259796066328175,2.1024328948841,log2_fold_induction,2,0.779388198984525,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90722804203707,1.90722804203707,1.8530451755629,20,transferase
LTEA_HepaRG_HMGCS2_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005509.1, , , ,"[60,60]",,Active,10.4609715237323,19.982292417161336,67.81717411114853,1.83133968910612,0.174504027621778,8.32272945970802,log2_fold_induction,2,0.523512082865334,,1.46532161306393,1.46532161306393,1.55812001242339,20,lyase
LTEA_HepaRG_HSPA1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_005337.2, , , ,,,Active,3.88374632562441,8.192580973250937,88.01371784979537,1.94455036672028,0.158018835916096,2.8556874889293,log2_fold_induction,2,0.474056507748288,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83743691416268,1.83743691416268,1.82526687078802,20,dna binding
LTEA_HepaRG_ICAM1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000192.2, , , ,,,Active,2.42284569741339,4.234107543839077,82.40371027254947,1.91594676648617,0.190740368332464,1.99817853169278,log2_fold_induction,2,0.572221104997392,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85222745864766,1.85222745864766,1.79666645156725,20,cell adhesion molecules
LTEA_HepaRG_IGF1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,4.99970810384887,10.27096589358826,90.11736418738697,1.95480848070366,0.162260237763032,3.41713505364802,log2_fold_induction,2,0.486780713289096,,1.24141084477571,1.24141084477571,1.25091357359705,20,growth factor
LTEA_HepaRG_IGFBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000587.1, , , ,,,Active,7.21360360028912,8.330664317735256,60.49116245580782,1.78169193040406,0.288636589078576,5.96421961628228,log2_fold_induction,2,0.865909767235728,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.50321704570278,1.50321704570278,1.47453754029278,20,transporter
LTEA_HepaRG_IL6_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000591.1, , , ,,,Active,3.9784876787903,4.968262833256026,84.6885511731668,1.92782470314783,0.266926812067961,3.12236193998287,log2_fold_induction,2,0.800780436203883,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85094148907226,1.85094148907226,1.8052634293379,20,cytokine
LTEA_HepaRG_KCNK1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002236.1, , , ,,,Active,1.69387973902612,2.3857413160952223,52.0300060704646,1.71625387656621,0.236667142353684,1.27982534245891,log2_fold_induction,2,0.710001427061052,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.63284585206148,1.63284585206148,1.15449310584606,20,ion channel
LTEA_HepaRG_KRT19_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002267.2, , , ,,,Active,2.11545742713084,3.9053113816749616,55.58811970523465,1.74498198406821,0.180562420456175,1.63680603254201,log2_fold_induction,2,0.541687261368525,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.50536072377363,1.50536072377363,1.25132826303155,20,filaments
LTEA_HepaRG_LDH_cytotoxicity,LDH leakage activity as a measure of membrane integrity and cytotoxicity in the cells.,, , , ,,,Active,64.7298078919179,6.788110078774733,44.52984390803976,1.64865117278683,0.9535762847205,68.4296284,percent_activity,2,9.535762847205,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.55333324153825,1.48177509418863,1.52936981605858,20,cell cycle
LTEA_HepaRG_LIPC_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000227.2, , , ,,,Active,4.4774618469936,8.612902243640717,62.85609497079407,1.79834739632337,0.173285060031091,3.73121820831027,log2_fold_induction,2,0.519855180093273,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.54380942938683,1.54380942938683,1.52282033764316,20,esterase
LTEA_HepaRG_LPL_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_000228.1, , , ,,,Active,0.602533107823122,1.5277598436404598,41.79479399624432,1.62112218896378,0.131463312189033,0.601967534568955,log2_fold_induction,2,0.394389936567099,"[""Borderline active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active"",""Borderline active""]",1.65583832754063,1.65583832754063,1.50177077429905,20,esterase
LTEA_HepaRG_MIR122_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,, , , ,,,Active,6.3390032514085,5.901094893956097,63.87342080504793,1.80532017585695,0.358069328111801,4.76306571514244,log2_fold_induction,2,1.0742079843354,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.52461446272178,1.52461446272178,1.41728019729305,20,microrna
LTEA_HepaRG_MMP10_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002416.1, , , ,,,Active,3.99389119962835,1.8107767190348272,36.965031552553896,1.5677910812381,0.735207744029526,3.99249031939005,log2_fold_induction,2,2.20562323208858,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.57917890012719,1.57917890012719,1.44850576477488,20,protease
LTEA_HepaRG_MMP3_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_002413.1, , , ,,,Active,5.1996810194349,5.53563022670761,57.78510330856452,1.76181589404812,0.313103826573539,3.67876208663291,log2_fold_induction,2,0.939311479720617,,1.30182130304919,1.30182130304919,1.09334006277093,20,protease
LTEA_HepaRG_MYC_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002458.2, , , ,,,Active,2.47239887967054,5.2618056441011,40.94755295998432,1.61222795328252,0.15662550379718,2.47044724941019,log2_fold_induction,2,0.46987651139154,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.53352864083446,1.53352864083446,1.49294747678927,20,dna binding
LTEA_HepaRG_NFE2L2_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_006155.2, , , ,"[61,61]",[478],Active,1.31670231533851,4.284576820983765,71.33286248209411,1.85328965196453,0.102437367823581,0.935040315799398,log2_fold_induction,2,0.307312103470743,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.64646979434561,1.64646979434561,1.4711712347504,20,dna binding
LTEA_HepaRG_NFKB1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_068810.3, , , ,,,Active,0.633119456946676,1.7940491619351302,1.153542844519937,0.0620337295836263,0.117633241864225,0.461322036448405,log2_fold_induction,0.477121254719662,0.352899725592675,"[""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",0.074991530390183,0.074991530390183,-0.061426703154432,20,dna binding
LTEA_HepaRG_NQO1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000894.1, , , ,,,Active,6.44782546912037,8.198138746556875,87.80255821528183,1.9435071696942,0.262166233436355,4.76538690195128,log2_fold_induction,2,0.786498700309065,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83635464205722,1.83635464205722,1.82422685496715,20,oxidoreductase
LTEA_HepaRG_PDK4_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_002603.1, , , ,,,Active,2.11172375427962,4.374937379499267,84.02541637220344,1.92441067321176,0.160895541360588,1.6904025954063,log2_fold_induction,2,0.482686624081764,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.85821134483971,1.85821134483971,1.8048302973792,20,kinase
LTEA_HepaRG_PEG10_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001165908.1, , , ,,,Active,0.951155313694665,1.399689037110994,20.79184249092323,1.31789297649767,0.226515863756396,0.880632711092882,log2_fold_induction,1.47712125471966,0.679547591269188,"[""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active""]",1.36771789916223,1.36771789916223,1.1985163414548,20,dna binding
LTEA_HepaRG_PEG10_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_001165908.1, , , ,,,Active,1.03070764241496,1.5167556410433476,91.31105315642984,1.96052335184202,0.226515863756396,0.695045487602925,log2_fold_induction,1.47712125471966,0.679547591269188,"[""Only one conc above baseline, active"",""Borderline active"",""Only one conc above baseline, active"",""Borderline active""]",1.99636269904829,1.99636269904829,1.8412430365602,20,dna binding
LTEA_HepaRG_PTEN_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000305.3, , , ,,,Active,4.31162104001636,7.9834983867336105,64.00253257001155,1.80619715928732,0.180022208775921,3.59301785901512,log2_fold_induction,2,0.540066626327763,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.5721337854578,1.5721337854578,1.54158354011094,20,phosphatase
LTEA_HepaRG_SLC22A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003048.1, , , ,,,Active,5.62103612278032,10.097375748632174,72.0772404990539,1.85779815118168,0.185560957048395,4.36894823650802,log2_fold_induction,2,0.556682871145185,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.60627502688266,1.60627502688266,1.60750091545881,20,transporter
LTEA_HepaRG_SLCO1B1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_006437.3, , , ,,,Active,2.00382204255572,3.692618557014485,36.79497306149595,1.56578848930452,0.180885371867909,2.0031212943636,log2_fold_induction,2,0.542656115603727,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.51201649220767,1.51201649220767,1.44650785890235,20,transporter
LTEA_HepaRG_SULT2A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003158.2, , , ,,,Active,6.03628179116548,10.755610248410097,83.34433178353014,1.92087606896496,0.187073897614124,4.88813131349451,log2_fold_induction,2,0.561221692842372,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79643458183938,1.79643458183938,1.80083884497019,20,transferase
LTEA_HepaRG_TGFA_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_003227.1, , , ,,,Active,3.21519931842919,7.139890250852551,69.25712212012293,1.84046444110721,0.150104983198459,2.37978593779158,log2_fold_induction,2,0.450314949595377,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.5296419381872,1.5296419381872,1.46414514519847,20,growth factor
LTEA_HepaRG_TGFB1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,P01137.2, , , ,,,Active,0.608315979398665,1.7766565993503018,37.01422039759794,1.56836860659984,0.114131224462307,0.562827072629525,log2_fold_induction,2,0.342393673386921,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.61175259283167,1.61175259283167,1.1912302204117,20,growth factor
LTEA_HepaRG_TIMP1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_003245.1, , , ,,,Active,0.542687013638396,1.4685256681200798,38.275868635477565,1.58292505539418,0.123181824560391,0.423379814046169,log2_fold_induction,2,0.369545473681173,"[""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active""]",1.8348524442468,1.8348524442468,0.852818158902373,20,protease inhibitor
LTEA_HepaRG_TNFRSF1A_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001056.1, , , ,,,Active,8.04062419745687,15.336907273812859,86.42291435725704,1.93662890751946,0.174755445668978,5.23614295277761,log2_fold_induction,2,0.524266337006934,"[""Noisy data"",""Noisy data""]",1.4526038061152,1.4526038061152,1.53723841058432,20,cytokine receptor
LTEA_HepaRG_TP53_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000537.3, , , ,"[46,46]",,Active,1.15902142784281,3.1504481873076413,42.83136053400991,1.63176186993774,0.122630322093241,0.87317440470867,log2_fold_induction,2,0.367890966279723,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.28806811075438,1.28806811075438,0.645480337066152,20,dna binding
LTEA_HepaRG_UGT1A1_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_000454.1, , , ,,,Active,4.50108818305938,6.7957734420585405,82.32343505184969,1.91552348363167,0.220778803248623,3.71774881593999,log2_fold_induction,2,0.662336409745869,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.82013455768704,1.82013455768704,1.79624316884445,20,transferase
LTEA_HepaRG_UGT1A6_dn,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _dn indicates curve fitting for decrease in expression (down).,NP_001063.2, , , ,,,Active,7.8916007320453,13.991666945491716,66.18601584494289,1.82076623894235,0.188007160804812,6.5763339989189,log2_fold_induction,2,0.564021482414436,"[""Noisy data"",""Noisy data""]",1.53491916836333,1.53491916836333,1.57583849521938,20,transferase
LTEA_HepaRG_XBP1_up,Change in transcription factor expression relative to control (delta-delta-ct) for HepaRG cell cultures in an induction preparation. The adherent cells have some metabolic capability. Expression measured by inducible reporter assay using Fluidigm qRT-PCR to monitor. Suffix _up indicates curve fitting for increase in expression (induction).,NP_005071.2, , , ,,,Active,1.6362974737787,3.159753127636085,90.11945658077184,1.95481856426924,0.172618704445313,1.14063152394521,log2_fold_induction,2,0.517856113335939,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.91301804043704,1.91301804043704,1.8355382223894,20,dna binding
NVS_ADME_hCYP2C19,"Data from the assay component NVS_ADME_hCYP2C19 was analyzed into 2 assay endpoints. This assay endpoint, NVS_ADME_hCYP2C19, was analyzed in the positive fitting direction relative to Acetonitrile as the negative control and baseline of activity. 
Using a type of enzyme reporter, loss-of-signal activity can be used to understand changes in the enzymatic activity as they relate to the gene CYP2C19. 
Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a enzymatic activity function. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""cyp"" intended target family, where the subfamily is ""xenobiotic metabolism"".",NP_000760.1, , , ,,,Active,99.5390809385202,4.97695404692601,0.7473879809605081,-0.126453890490261,2.60299124232151,98.0535665730083,percent_activity,1.30102999566398,20,,-0.547959372863544,-0.878644443904055,-0.797320482038136,20,cyp
NVS_NR_hAR,"Data from the assay component NVS_NR_hAR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hAR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",, , , ,"[307,111,19,23,187,117,307,19,23,111,187,117]",,Active,27.5010858460914,1.2559428889128303,14.808104474693948,1.17049946980637,3.64946077416744,22.9175715389692,percent_activity,1.69897000433602,21.8967646450046,"[""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",1.93769517690905,0.937797638386761,-0.066439250993868,20,nuclear receptor
NVS_NR_hGR,"Data from the assay component NVS_NR_hGR was analyzed into 1 assay endpoint. This assay endpoint, NVS_NR_hGR, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene NR3C1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000167.1, , , ,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,42.441737713278,1.4664714407487702,6.455927990328114,0.809958677603488,4.82356679827413,46.5067778936392,percent_activity,1.30102999566398,28.9414007896448,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting""]",0.85135825221413,0.774178960411474,0.690670563822471,20,nuclear receptor
NVS_TR_gDAT,"Data from the assay component NVS_TR_gDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_gDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene Slc6a3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",NP_034150.1, , , ,,,Active,34.6048087426805,1.5567713986736738,28.872552092436635,1.46048517358201,3.70476238752447,28.8373408901733,percent_activity,1.69897000433602,22.2285743251468,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Hit-call potentially confounded by overfitting"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only highest conc above baseline, active""]",1.54832425562617,1.34823161137589,1.13090523436685,20,transporter
NVS_TR_hDAT,"Data from the assay component NVS_TR_hDAT was analyzed into 1 assay endpoint. This assay endpoint, NVS_TR_hDAT, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, loss-of-signal activity can be used to understand changes in the binding as they relate to the gene SLC6A3. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""transporter"" intended target family, where the subfamily is ""neurotransmitter transporter"".",NP_001035.1, , , ,,,Active,58.8353728014599,2.9417686400729948,12.099374369766613,1.08276291454929,3.32006520794786,49.0294773645187,percent_activity,1.69897000433602,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",0.815526363838919,0.442186600509388,0.19792355293026,20,transporter
OT_AR_ARSRC1_0480,"Data from the assay component OT_AR_ARSRC1_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,65.3764288875336,3.2688214443766803,52.80685589838616,1.72269031051765,2.45637869822485,50.5632040050062,percent_activity,2,20,,1.53122623431483,1.24049722663954,1.20919116195472,20,nuclear receptor
OT_AR_ARSRC1_0960,"Data from the assay component OT_AR_ARSRC1_0960 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_AR_ARSRC1_0960, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene AR. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_005408.1, , , ,,,Active,48.7997596397222,2.4399879819861097,36.83562476589778,1.56626804028513,1.6382320441989,46.9194312796209,percent_activity,2,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.51406556029738,1.25283333389569,1.25170513464863,20,nuclear receptor
OT_ER_ERaERa_0480,"Data from the assay component OT_ER_ERaERa_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERa_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_000116.2, , , ,"[30,200,29,165,53,52,167,112,30,67,200,29,165,53,52,67,112,167]",[1181],Active,25.0566861171426,1.25283430585713,11.992435875045683,1.07890740492086,1.66499024557606,20.5847457627119,percent_activity,1.47712125471966,20,"[""Borderline active"",""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy""]",1.15694174421435,1.00000131810481,0.954211870923728,20,nuclear receptor
OT_ER_ERaERb_0480,"Data from the assay component OT_ER_ERaERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1", , , ,,,Active,58.7202308649887,2.5202084217545133,20.295333410291082,1.30739619027071,4.65995037220843,44.3363015117001,percent_activity,1.47712125471966,23.2997518610421,"[""Only one conc above baseline, active"",""Less than 50% efficacy"",""Only one conc above baseline, active"",""Less than 50% efficacy""]",1.24061835757147,1.12193501665548,0.957087511137462,20,nuclear receptor
OT_ER_ERaERb_1440,"Data from the assay component OT_ER_ERaERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERaERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR1 and ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".","NP_000116.2|NP_001428.1", , , ,,,Active,73.1267604120934,3.6563380206046703,21.723895629301502,1.33693770759291,1.91268599454975,47.2769953051643,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.1059637273171,0.754541321837841,0.817461285631346,20,nuclear receptor
OT_ER_ERbERb_0480,"Data from the assay component OT_ER_ERbERb_0480 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_0480, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1, , , ,,,Active,57.2277408108097,2.861387040540485,13.90966285637453,1.14331660365196,3.03794948946985,33.4183905950971,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Only one conc above baseline, active""]",1.09115255781267,1.00363171956647,0.958845208166492,20,nuclear receptor
OT_ER_ERbERb_1440,"Data from the assay component OT_ER_ERbERb_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_ER_ERbERb_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene ESR2. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""steroidal"".",NP_001428.1, , , ,,,Active,29.3449647514452,1.46724823757226,14.837958107612575,1.17137414059193,1.48426296250401,24.3280496209511,percent_activity,1.47712125471966,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.30814129722515,0.862028523928892,0.776433558647734,20,nuclear receptor
OT_FXR_FXRSRC1_1440,"Data from the assay component OT_FXR_FXRSRC1_1440 was analyzed into 1 assay endpoint. 
This assay endpoint, OT_FXR_FXRSRC1_1440, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as they relate to the gene NR1H4. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the ""nuclear receptor"" intended target family, where the subfamily is ""non-steroidal"".","NP_005408.1|NP_001193922.1", , , ,,,Active,59.4662053447029,1.4287164338236291,13.583465818658842,1.13301059423598,8.32442378863878,46.1395900515216,percent_activity,1.47712125471966,41.6221189431939,"[""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Borderline active"",""Only one conc above baseline, active"",""Less than 50% efficacy"",""Hit-call potentially confounded by overfitting"",""Only one conc above baseline, active"",""Borderline active""]",1.17909411453364,1.11543880112091,1.0134584376128,20,nuclear receptor
TOX21_AP1_BLA_Agonist_ch1,"Data from the assay component TOX21_AP1_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,41.2669211991852,2.06334605995926,26.960822478651995,1.43073313684294,2.57591984669775,38.4874999634,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.41827221957945,1.13292887582592,0.984963555438935,20,channel 1
TOX21_AP1_BLA_Agonist_ratio,"Data from the assay component TOX21_AP1_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AP1_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene JUN|FOS|JUN. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is basic leucine zipper.",NP_002219.1, , , ,,,Active,37.5258423092613,1.876292115463065,21.544700473362422,1.33334046065831,2.7369041511147,36.7912470475,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.35325346668674,1.14143240921798,1.00201572232564,20,dna binding
TOX21_AP1_BLA_Agonist_viability,"TOX21_AP1_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle target family, where the subfamily is cytotoxicity.",, , , ,,,Active,79.4349238089441,3.5209558633707143,155.61302852408062,2.19204595498815,3.76010222277627,26.4596217912,percent_activity,1.90308998699194,22.5606133366576,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Borderline active""]",1.87983763999792,1.58469972578557,1.45014298459952,20,cell cycle
TOX21_AR_BLA_Antagonist_ch2,"Data from the assay component TOX21_AR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,140.424740968276,2.659516850450597,73.00148711245198,1.86333170721845,8.80014108229746,77.6363067431,percent_activity,1.90308998699194,52.8008464937848,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.76232193896298,1.57157897387568,1.4251687627184,20,channel 2
TOX21_AR_BLA_Antagonist_ratio,"Data from the assay component TOX21_AR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,"[307,19,23,111,187,117,307,111,19,23,187,117]",,Active,84.2370345369127,3.2284075235951826,36.63030814379575,1.56384057207943,4.34874025461246,78.5225568555,percent_activity,1.90308998699194,26.0924415276748,,1.46897232397232,1.36294052687,1.30370058438708,20,nuclear receptor
TOX21_AR_BLA_Antagonist_viability,"TOX21_AR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,58.4991374917264,2.536912299169555,42.02763115702868,1.62353491214621,3.8431979898606,56.27460721,percent_activity,1.90308998699194,23.0591879391636,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.60020377537841,1.54728461807139,1.50425459330092,20,cell cycle
TOX21_ARE_BLA_Agonist_ch1,"Data from the assay component TOX21_ARE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ARE_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,85.7346343635945,4.286731718179725,47.176702832903025,1.67372758488544,2.85455403754395,69.6997355754,percent_activity,1.95424250943932,20,,1.43123196354846,1.22568291007572,1.22594191167648,20,channel 1
TOX21_ARE_BLA_agonist_ratio,"Data from the assay component TOX21_ARE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_ARE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFE2L2. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.  ",NP_006155.2, , , ,"[61,61]",[478],Active,53.0787688146927,2.653938440734635,22.497605279110246,1.35213629280392,2.50978290890691,50.0848246527,percent_activity,1.60205999132796,20,,1.32481095205206,1.25438332546573,1.23281046291752,20,dna binding
TOX21_ARE_BLA_agonist_viability,"TOX21_ARE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,91.111901439318,3.0783162602023846,39.73224092447188,1.59914306024003,4.93299441089742,87.718873598,percent_activity,1.95424250943932,29.5979664653845,,1.52434825940459,1.43143976942368,1.37449790884152,20,cell cycle
TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881,"Data from the assay component TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_AR_LUC_MDAKB2_Antagonist_0.5nM_R1881, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene AR. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",, , , ,,,Active,115.876819658123,3.6068768049612987,34.08455033823348,1.53255756892529,5.35443940025589,87.1554936398,percent_activity,1.95424250943932,32.1266364015353,,1.17550702465556,0.851823304961572,0.71377358471544,20,nuclear receptor
TOX21_Aromatase_Inhibition,"Data from the assay component TOX21_Aromatase_Inhibition was analyzed into 1 assay endpoint. This assay endpoint, TOX21_Aromatase_Inhibition, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. 
Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene CYP19A1. 
Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. 
To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cyp intended target family, where the subfamily is steroidogenesis-related.",NP_000094.2, , , ,"[122,123,7,153,25,122,123,7,153,25]",[964],Active,74.0337312062923,2.7587348004305485,53.82712265087704,1.73100116506099,4.47268624701549,61.4520716699,percent_activity,1.95424250943932,26.8361174820929,,1.645151645493,1.50170932278498,1.39690189236192,20,cyp
TOX21_Aromatase_Inhibition_viability,"TOX21_Aromatase_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,63.6521670322996,2.3042582497283925,47.73263510209382,1.67881541045485,4.60395205556223,59.1084240078,percent_activity,1.95424250943932,27.6237123333734,,1.64948712278255,1.53712862726401,1.43622328723492,20,cell cycle
TOX21_CAR_Agonist,"Data from the assay component TOX21_CAR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_CAR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1I3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_001070948.1, , , ,,,Active,27.0319134817998,1.3515956740899902,53.69764903528,1.72995527204303,0.83822208889671,21.9646472888,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Borderline active"",""Less than 50% efficacy""]",1.91452645719737,1.32784776859975,1.34197607177598,20,nuclear receptor
TOX21_CASP3_CHO_viability,"The assay component endpoint  TOX21_CASP3_CHO_viability uses a type of viability reporter where loss-of-signal activity can be used to understand changes in viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to cell cycle, where the subfamily is cytotoxicity.",, , , ,,,Active,44.4236780015458,2.22118390007729,69.19233055379723,1.84005795886781,2.57636017956492,36.310034032,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.82472511297702,1.72053562389401,1.67145836287046,20,cell cycle
TOX21_DT40,"Data from the assay component TOX21_DT40 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.",, , , ,,,Active,111.617291880383,4.650600717836795,57.02219142704447,1.75604390372028,4.0001030208237,85.0627761286,percent_activity,1.95424250943932,24.0006181249422,,1.51438632338259,1.36107330404988,1.34598956422596,20,cell cycle
TOX21_DT40_100,"Data from the assay component TOX21_DT40_100 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_100, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the viability as they relate to the gene Ku70 - Rad54 (-/-). Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,132.798610767429,6.156807752421743,52.0324455471344,1.71627423840163,3.59489896137582,97.995335552,percent_activity,1.95424250943932,21.5693937682549,,1.33966239506869,1.15927060705482,1.21179831863331,20,cell cycle
TOX21_DT40_657,"Data from the assay component TOX21_DT40_657 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_DT40_657, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of viability reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene Rev3. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA repair family.",, , , ,,,Active,98.4307285495848,3.7566090827649705,49.63719617973529,1.69580724184241,4.36700254498032,78.2009106118,percent_activity,1.95424250943932,26.2020152698819,,1.50076215994238,1.33537177539014,1.27316692130461,20,cell cycle
TOX21_ELG1_LUC_Agonist_viability,"TOX21_ELG1_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,73.0137805267669,2.261079436505076,79.80372295833084,1.90202315228487,5.38192653679485,51.3338410573,percent_activity,1.95424250943932,32.2915592207691,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.88943034659852,1.83367203358292,1.78274283687165,20,cell cycle
TOX21_ERa_BLA_Agonist_ch1,"Data from the assay component TOX21_ERa_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,37.4484039751274,1.87242019875637,42.85102397343199,1.63196120433851,2.92546209770346,38.6993196217,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.63937049057216,1.56769338659173,1.51268088679695,20,channel 1
TOX21_ERa_BLA_Antagonist_ratio,"Data from the assay component TOX21_ERa_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,47.2775295166352,2.36387647583176,41.697082760840956,1.62010567163593,3.3294568553358,46.9797028449,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.60325879085757,1.54859467492445,1.50082535131811,20,nuclear receptor
TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2,"Data from the assay component TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ERa_LUC_VM7_Antagonist_0.5nM_E2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ESR1. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000116.2, , , ,"[200,29,165,53,52,167,112,30,67,200,29,165,53,52,30,67,112,167]",[1181],Active,87.3267905861326,3.56466863497951,77.34457635292236,1.88842986499619,4.08297841624554,64.1410621589,percent_activity,1.95424250943932,24.4978704974732,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.83730095728926,1.79000317482161,1.76914955099693,20,nuclear receptor
TOX21_ESRE_BLA_ch1,"Data from the assay component TOX21_ESRE_BLA_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene ATF6. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,90.8302379567517,4.41149072358497,66.7723880201412,1.82459690843993,3.43157765511288,74.1429234458,percent_activity,1.90308998699194,20.5894659306773,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.757978883551,1.71292536997979,1.70531659377223,20,channel 1
TOX21_ESRE_BLA_ratio,"Data from the assay component TOX21_ESRE_BLA_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_ESRE_BLA_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene ATF6.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is basic leucine zipper.",NP_031374.2, , , ,,,Active,253.085445642146,12.6542722821073,77.35240460133654,1.88847381886098,1.43781423195858,143.624032262,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.7551631735339,1.66835163465483,1.7691935049353,20,dna binding
TOX21_ESRE_BLA_viability,"TOX21_ESRE_BLA_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,108.554610416905,2.4374433712995223,53.74506500973056,1.73033859254229,7.42270991093352,88.5978242239,percent_activity,1.90308998699194,44.5362594656011,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.68438190248883,1.55879021112654,1.4520619247933,20,cell cycle
TOX21_FXR_BLA_antagonist_ratio,"Data from the assay component TOX21_FXR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_FXR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, measures of receptor for gain-of-signal activity can be used to understand the reporter gene at the pathway-level as they relate to the gene NR1H4. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_001193922.1, , , ,"[27,61,27,61]",[479],Active,33.1151710021188,1.65575855010594,38.798082879014416,1.58881026642835,2.78938673282934,24.1576057579,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.70708737096384,1.28488667936,0.972923105609621,20,nuclear receptor
TOX21_GR_BLA_Agonist_ch1,"Data from the assay component TOX21_GR_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Agonist_ch1, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,55.8968909589257,2.55881846948747,73.94091824620477,1.86888483962069,3.6408008634627,35.3825412303,percent_activity,1.90308998699194,21.8448051807762,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.84478539645201,1.79205383221121,1.74960452438887,20,channel 1
TOX21_GR_BLA_Antagonist_ch2,"Data from the assay component TOX21_GR_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,179.422799249199,3.599137498810277,70.02119434768132,1.84522951422941,8.30860168158384,132.9047152589,percent_activity,1.90308998699194,49.851610089503,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79337585690597,1.74619565830633,1.72594919952602,20,channel 2
TOX21_GR_BLA_Antagonist_ratio,"Data from the assay component TOX21_GR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_GR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR3C1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand gene activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000167.1, , , ,"[64,66,214,71,14,318,64,214,66,71,14,318]",,Active,92.8646222815054,2.439733535210406,60.797626349220955,1.78388662395105,6.34390470252021,60.0654753114,percent_activity,1.90308998699194,38.0634282151213,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.72978485848107,1.58264084641282,1.45772088748911,20,nuclear receptor
TOX21_GR_BLA_Antagonist_viability,"TOX21_GR_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,118.792060361866,3.053166483576528,72.14442462647676,1.85820277413339,6.48463712459766,81.0245260368,percent_activity,1.90308998699194,38.907822747586,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.819149727873,1.76968907505741,1.73892238257886,20,cell cycle
TOX21_H2AX_HTRF_CHO_Agonist_ch2,"Data from the assay component TOX21_H2AX_HTRF_CHO_Agonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_H2AX_HTRF_CHO_Agonist_ch2, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene H2AFX. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,45.926062254903,2.29630311274515,90.12938522732013,1.95486640875323,3.30482924833509,46.1970235749,percent_activity,2.30102999566398,20,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.94073971233212,1.88465419473798,1.83526118099371,20,channel 2
TOX21_HDAC_Inhibition_viability,"TOX21_HDAC_Inhibition_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,25.6398729969387,1.2819936498469349,46.598508187620894,1.66837201333689,1.94086260138813,22.107161773,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Borderline active"",""Less than 50% efficacy"",""Borderline active""]",1.86605194248629,1.47710421777755,1.32525072167881,20,cell cycle
TOX21_HRE_BLA_Agonist_ch1,"Data from the assay component TOX21_HRE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,106.655662782576,5.3327831391288,48.18853128045838,1.68294368980997,2.28898316931438,88.6519225513,percent_activity,1.90308998699194,20,,1.47304793502807,1.29981211813482,1.36839933266921,20,channel 1
TOX21_HRE_BLA_Agonist_ratio,"Data from the assay component TOX21_HRE_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HRE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HIF1A. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the dna binding intended target family, where the subfamily is hypoxia-response element.",NP_001521.1, , , ,,,Active,213.69919116424,10.684959558212,60.34577003472479,1.78064683342325,0.3624938875215,176.0299334895,percent_activity,1.90308998699194,20,"[""Noisy data"",""Noisy data""]",1.60283416845904,1.36750506201048,1.60857830063055,20,dna binding
TOX21_HRE_BLA_Agonist_viability,"TOX21_HRE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,121.735385547712,6.0867692773856,63.02447918738139,1.79950926550309,3.0508964104962,99.2532735299,percent_activity,1.90308998699194,20,"[""Noisy data"",""Noisy data""]",1.68864582610196,1.62846536124212,1.64975797567683,20,cell cycle
TOX21_HSE_BLA_agonist_ch1,"Data from the assay component TOX21_HSE_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_HSE_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,56.8069222552669,2.8403461127633447,53.26107626437778,1.72640993812541,3.14273554940163,53.2954333887,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.69329749742409,1.63876565856485,1.60712961660016,20,channel 1
TOX21_HSE_BLA_agonist_ratio,"Data from the assay component TOX21_HSE_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_HSE_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene HSF1.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is heat shock protein.",NP_005517.1, , , ,,,Active,40.974353268875,2.04871766344375,42.47991261977418,1.62818361474034,0.91844270028357,39.8593010886,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.62560128710284,1.4854200648553,1.50890308017032,20,dna binding
TOX21_HSE_BLA_agonist_viability,"TOX21_HSE_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,75.9512912624578,1.6254564804262446,51.57995269367,1.7124809394908,7.78768837934283,57.9323758125,percent_activity,1.90308998699194,46.726130276057,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79011434287452,1.57825907715022,1.34898713030072,20,cell cycle
TOX21_MMP_ratio_down,"Data from the assay component TOX21_MMP_ratio was analyzed into 2 assay endpoints. This assay endpoint, TOX21_MMP_ratio_down, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of 6 membrane potential reporter, loss-of-signal activity can be used to understand changes in the signaling. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a signaling function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell morphology intended target family, where the subfamily is organelle conformation.",, , , ,,,Active,88.3707166134924,2.285635843968267,10.135181494387437,1.00583153016817,6.44391923052108,90.8870356515,percent_activity,1.60205999132796,38.6635153831265,,0.970683111061491,0.827759574962115,0.698456723122387,20,cell morphology
TOX21_MMP_viability,"TOX21_MMP_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,41.3372612596794,2.06686306298397,72.68613910858615,1.86145160091979,3.32276785161468,29.6138729822,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.85472214152123,1.7422551287718,1.63299774240603,20,cell cycle
TOX21_NFkB_BLA_agonist_ch1,"Data from the assay component TOX21_NFkB_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_NFkB_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,103.274433100389,5.16372165501945,68.48018483256712,1.83556492386033,3.27484652838546,79.5218186214,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.75811075799575,1.7132516656546,1.71625541255545,20,channel 1
TOX21_NFkB_BLA_agonist_ratio,"Data from the assay component TOX21_NFkB_BLA_Agonist_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_NFkB_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NFKB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is NF-kappa B.",NP_068810.3, , , ,,,Active,49.0299254597902,2.45149627298951,67.99366391372716,1.83246844424281,0.28322094145254,38.8039867109,percent_activity,1.90308998699194,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.81224145346075,1.61326562430083,1.71318812965889,20,dna binding
TOX21_NFkB_BLA_agonist_viability,"TOX21_NFkB_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,129.343393466172,5.270776749535364,51.106810975395234,1.70847878216834,4.08995358155937,98.1879722591,percent_activity,1.90308998699194,24.5397214893562,,1.45859259918967,1.32023039526629,1.33028779049095,20,cell cycle
TOX21_p53_BLA_p1_ch1,"Data from the assay component TOX21_p53_BLA_p1_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,92.9312630402634,4.6465631520131705,60.628666492797734,1.78267801617842,3.00976293237186,88.1755740777,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.71244237291826,1.66166288365286,1.66339740383137,20,channel 1
TOX21_p53_BLA_p1_ratio,"Data from the assay component TOX21_p53_BLA_p1_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p1_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,251.711741856383,12.58558709281915,74.02811428496713,1.86939668675808,1.19928273802848,207.2980087705,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.73640693096568,1.63957065590451,1.75011637307392,20,dna binding
TOX21_p53_BLA_p1_viability,"TOX21_p53_BLA_p1_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,128.273737433643,3.057587188991514,64.0373011830795,1.8064330205303,6.99210027956454,105.7000125275,percent_activity,1.95424250943932,41.9526016773872,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.73708627963636,1.64956093580952,1.59525744549499,20,cell cycle
TOX21_p53_BLA_p2_ch1,"Data from the assay component TOX21_p53_BLA_p2_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p2_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,50.8082628858014,2.5404131442900697,73.68372352726617,1.86737156434521,2.8966141715805,42.3402191043,percent_activity,1.95424250943932,20,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.84391691235704,1.78168904316602,1.74809125058925,20,channel 1
TOX21_p53_BLA_p2_viability,"TOX21_p53_BLA_p2_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,54.7836965167844,1.552345489592442,73.91047640966923,1.86870600164836,5.8818195738939,45.6530805596,percent_activity,1.95424250943932,35.2909174433634,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.90092965017612,1.82830745916507,1.7494256878906,20,cell cycle
TOX21_p53_BLA_p3_ch1,"Data from the assay component TOX21_p53_BLA_p3_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p3_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,84.4712145650711,4.1123336364344105,34.67623174044101,1.54003189666892,3.42349065166122,82.69694031,percent_activity,1.95424250943932,20.5409439099673,,1.41807223616187,1.32761235439678,1.30401007097665,20,channel 1
TOX21_p53_BLA_p3_ratio,"Data from the assay component TOX21_p53_BLA_p3_ratio was analyzed into 1 assay endpoint.  This assay endpoint, TOX21_p53_BLA_p3_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity.  Using a type of inducible reporter,  gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53.  Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,135.877015855375,6.793850792768749,49.952954887264006,1.6985611833183,0.8227628069073,134.6641181022,percent_activity,1.95424250943932,20,,1.60319026986708,1.48196264111889,1.57928086950577,20,dna binding
TOX21_p53_BLA_p3_viability,"TOX21_p53_BLA_p3_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,115.318088511629,3.825986047997016,37.145661386814005,1.569908095464,5.02345831309728,98.8247624615,percent_activity,1.95424250943932,30.1407498785837,,1.34541428641762,1.16042327005585,1.09509476713834,20,cell cycle
TOX21_p53_BLA_p4_viability,"TOX21_p53_BLA_p4_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,40.8303291823827,1.706082845216627,73.79763679019409,1.86804245470365,3.98870130064896,34.0256962853,percent_activity,1.95424250943932,23.9322078038938,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.88693549734811,1.82024156230191,1.74876214000865,20,cell cycle
TOX21_p53_BLA_p5_ch1,"Data from the assay component TOX21_p53_BLA_p5_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,85.7977573255355,3.659482749744268,60.49326077781282,1.78170699498252,3.90755393557242,80.8504396824,percent_activity,1.95424250943932,23.4453236134345,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.7212967972453,1.6678475233039,1.64600463698292,20,channel 1
TOX21_p53_BLA_p5_ratio,"Data from the assay component TOX21_p53_BLA_p5_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_p53_BLA_p5_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TP53. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity.  To generalize the intended target to other relatable targets, this assay endpoint is annotated to the DNA binding intended target family, where the subfamily is tumor suppressor.",NP_000537.3, , , ,"[46,46]",,Active,130.675672500229,6.53378362501145,73.62556406985522,1.86702863508191,1.35224934572532,108.8963937613,percent_activity,1.95424250943932,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.77415086332953,1.6802385618686,1.74774832138367,20,dna binding
TOX21_p53_BLA_p5_viability,"TOX21_p53_BLA_p5_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,96.7572495341592,2.1867828441655073,48.88363374383046,1.68916348152743,7.374398559381,96.0293840001,percent_activity,1.95424250943932,44.246391356286,,1.67986664679641,1.62314930119394,1.56987768555312,20,cell cycle
TOX21_PPARd_BLA_Agonist_viability,"TOX21_PPARd_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,50.8015593655691,1.5235500882855417,38.18388589958778,1.58188012360904,5.55736672264977,49.5388865889,percent_activity,1.90308998699194,33.3442003358986,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.61701034584556,1.54298773455718,1.46259980353988,20,cell cycle
TOX21_PPARg_BLA_Agonist_ch1,"Data from the assay component TOX21_PPARg_BLA_Agonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,77.2158872705536,2.7987264946067576,66.92409791312542,1.82558252593305,4.59827516904273,62.8943162349,percent_activity,1.90308998699194,27.5896510142564,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79371188442432,1.74276786367865,1.70630221208456,20,channel 1
TOX21_PPARg_BLA_Agonist_ratio,"Data from the assay component TOX21_PPARg_BLA_Agonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Agonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.",NP_056953.2, , , ,"[34,36,58,72,163,72,36,58,34,163]",,Active,77.4227723846117,3.871138619230585,69.74266110510605,1.84349851432207,2.08360537976913,55.8862272875,percent_activity,1.90308998699194,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.78624172900961,1.71145195696549,1.72421816896112,20,nuclear receptor
TOX21_PPARg_BLA_Antagonist_ch2,"Data from the assay component TOX21_PPARg_BLA_Antagonist_ch2 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PPARg_BLA_Antagonist_ch2, was analyzed in the negative fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene PPARG. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,162.343707503126,1.7687621110089373,43.34157099556806,1.6369046490775,15.2972999678404,171.6718791557,percent_activity,1.90308998699194,91.7837998070424,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.65118065424629,1.58635336919138,1.5176243228398,20,channel 2
TOX21_PPARg_BLA_antagonist_viability,"TOX21_PPARg_BLA_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,97.122193620492,1.7727099063882836,21.157102223487016,1.32545618441562,9.1312358619699,97.1084899739,percent_activity,1.90308998699194,54.7874151718194,,1.33945417454706,1.27473607521067,1.20617544347197,20,cell cycle
TOX21_PR_BLA_Antagonist_ratio,"Data from the assay component TOX21_PR_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PR_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity an be used to understand changes in the reporter gene as they relate to the gene NR3C3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is steroidal.",NP_000917.3, , , ,,,Active,66.6523634885277,3.332618174426385,42.944053359719874,1.63290303378164,2.51198214229767,53.9545240781,percent_activity,1.95424250943932,20,,1.25126728337273,0.704791310817487,0.642881726806599,20,nuclear receptor
TOX21_PXR_Agonist,"Data from the assay component TOX21_PXR_Agonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_PXR_Agonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, gain-of-signal activity can be used to understand changes in the reporter gene as they relate to gene NR1I2. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor target family, where the subfamily is non-steroidal.",NP_071285.1, , , ,,,Active,121.913897365888,6.0956948682944,25.291972716038615,1.40298270464204,1.80636679455099,120.7573529517,percent_activity,1.95424250943932,20,,1.25370162192021,1.1217354349708,1.20155500776904,20,nuclear receptor
TOX21_RAR_LUC_Agonist_viability,"TOX21_RAR_LUC_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,22.4977555853383,1.124887779266915,53.725445406042645,1.73018002465831,1.53553439731881,22.2391206793,percent_activity,1.95424250943932,20,"[""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Borderline active"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.84311505005724,1.65652282388229,1.61089969166123,20,cell cycle
TOX21_RORg_LUC_CHO_Antagonist,"Data from the assay component TOX21_RORg_LUC_CHO_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_RORg_LUC_CHO_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene NR1F3. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints where this one serves a reporter gene function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family.",NP_005051.2, , , ,,,Active,101.20672545617,1.9423517596207587,79.47586922664223,1.9002352864864,8.68420845631059,69.6291500022,percent_activity,1.95424250943932,52.1052507378635,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.90345865580908,1.84272263751054,1.78095497087689,20,nuclear receptor
TOX21_RORg_LUC_CHO_Antagonist_viability,"TOX21_RORg_LUC_CHO_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,81.4313600571757,4.071568002858784,48.42627152950466,1.68508103281908,3.0881472477345,75.3469351042,percent_activity,1.95424250943932,20,,1.5596807670048,1.45568863947114,1.43954953405951,20,cell cycle
TOX21_RT_HEK293_FLO_32hr_viability,"TOX21_RT_HEK293_FLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,41.0756354367846,1.444803120829161,39.10726595639229,1.59225745487934,4.73831980341741,34.2296962264,percent_activity,1.90308998699194,28.4299188205045,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.77203187860949,1.45104099577495,1.10467158367145,20,cell cycle
TOX21_RT_HEK293_FLO_40hr_viability,"TOX21_RT_HEK293_FLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_GLO_08hr_viability",, , , ,,,Active,51.7491496443178,1.8133423743564774,42.48780528120977,1.62826429807287,4.75633195144065,43.124291398,percent_activity,1.90308998699194,28.5379917086439,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.66930371314072,1.43643426224233,1.19181006847295,20,cell cycle
TOX21_RT_HEK293_GLO_08hr_viability,"TOX21_RT_HEK293_GLO_08hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,55.8251048511559,2.299335749392197,33.37516164337288,1.52342337776304,4.04646609105207,55.0067444894,percent_activity,1.90308998699194,24.2787965463124,,1.49979083907324,1.40785099128257,1.32512142685646,20,cell cycle
TOX21_RT_HEK293_GLO_16hr_viability,"TOX21_RT_HEK293_GLO_16hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,56.9259915981189,2.3614617336109065,40.78206490073361,1.61046921144435,4.0177086637968,47.4383263679,percent_activity,1.90308998699194,24.1062519827808,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.55150268607701,1.35926260025766,1.19057308278876,20,cell cycle
TOX21_RT_HEK293_GLO_24hr_viability,"TOX21_RT_HEK293_GLO_24hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,47.6121020946663,1.940565841704339,34.199472855736886,1.534019411974,4.08919407864135,46.7854838737,percent_activity,1.90308998699194,24.5351644718481,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.53962472898703,1.43721671701849,1.33301710157299,20,cell cycle
TOX21_RT_HEK293_GLO_32hr_viability,"TOX21_RT_HEK293_GLO_32hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,46.2457509069057,1.8408174772110302,33.603253220337756,1.52638132462936,4.18706647811088,45.6323373508,percent_activity,1.90308998699194,25.1223988686653,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.54154285139487,1.44012180087554,1.33424180516144,20,cell cycle
TOX21_RT_HEK293_GLO_40hr_viability,"TOX21_RT_HEK293_GLO_40hr_viability used a dead cell DNA stain where an increase in measured fluorescence indicated a loss of cell viability.  The assay component endpoint is part of a kinetic analysis of cell death with additional exposure times measured in other assay components as well as live cells measured with a vital dye, e.g. TOX21_RT_HEK293_FLO_08hr_viability",, , , ,,,Active,42.2658375620811,1.6970569412551948,31.923235841725912,1.50410690639361,4.15089564121323,42.2225670667,percent_activity,1.90308998699194,24.9053738472794,"[""Less than 50% efficacy"",""Less than 50% efficacy""]",1.52369846515545,1.45671358614351,1.38482603994076,20,cell cycle
TOX21_RXR_BLA_Agonist_viability,"TOX21_RXR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,55.1385888201226,2.0705242667152426,54.3190524592133,1.73495218551169,4.43837580224682,45.8852162098,percent_activity,1.90308998699194,26.6302548134809,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.72706890137601,1.60255212090241,1.48078156809151,20,cell cycle
TOX21_SBE_BLA_Antagonist_ratio,"Data from the assay component TOX21_SBE_BLA_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_SBE_BLA_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TGFB1. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this ratio serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the growth factor receptor intended target family, where subfamily is transforming growth factor beta.",NP_005891.1, , , ,,,Active,26.3155463254376,1.2898242308709147,34.99107265337353,1.54395725600965,3.40040470833105,28.0459246175,percent_activity,1.90308998699194,20.4024282499863,"[""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active""]",1.61119041957456,1.51913719987131,1.42467694221076,20,growth factor receptor
TOX21_TR_LUC_GH3_Antagonist,"Data from the assay component TOX21_TR_LUC_GH3_Antagonist was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TR_LUC_GH3_Antagonist, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene THRA and THRB. Furthermore, this assay endpoint can be referred to as a primary readout, because the performed assay has only produced 1 assay endpoint. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the nuclear receptor intended target family, where the subfamily is non-steroidal.","NP_003241.2|NP_000452.2", , , ,,,Active,152.909356250382,6.815131700839904,78.11971043792266,1.89276062484309,3.73945711206963,115.030398762,percent_activity,1.95424250943932,22.4367426724178,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.79719067826837,1.75508407071253,1.77348030842671,20,nuclear receptor
TOX21_TR_LUC_GH3_Antagonist_viability,"TOX21_TR_LUC_GH3_Antagonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,142.916838004661,3.5662035253743647,79.54625383913942,1.90061973174754,6.67922423139783,103.2848177755,percent_activity,1.95424250943932,40.075345388387,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",1.84945834349846,1.80216585785966,1.78133941552317,20,cell cycle
TOX21_TSHR_HTRF_Antagonist_ch1,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ch1 was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ch1, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, increased activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves as artifact detection function.",, , , ,,,Active,131.627708716724,6.581385435836199,68.84164283126229,1.83785122574673,1.90228676304723,90.0164007945,percent_activity,1.95424250943932,20,,1.57698629607187,1.36844639307364,1.50449860839374,20,channel 1
TOX21_TSHR_HTRF_Antagonist_ratio,"Data from the assay component TOX21_TSHR_HTRF_Antagonist_ratio was analyzed into 1 assay endpoint. This assay endpoint, TOX21_TSHR_HTRF_Antagonist_ratio, was analyzed in the positive fitting direction relative to DMSO as the negative control and baseline of activity. Using a type of inducible reporter, loss-of-signal activity can be used to understand changes in the reporter gene as they relate to the gene TSHR. Furthermore, this assay endpoint can be referred to as a primary readout, because this assay has produced multiple assay endpoints and this one serves a reporter gene function to understand target activity. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the gpcr intended target family, where the subfamily is thyrotropin-releasing hormone receptor.",, , , ,,,Active,106.188711640426,5.3094355820213,60.39560489471228,1.7810053353194,1.7350029827067,87.8208629064,percent_activity,1.95424250943932,20,,1.61983540664968,1.45384145335641,1.53858690295752,20,gpcr
TOX21_VDR_BLA_Agonist_viability,"TOX21_VDR_BLA_Agonist_viability used a type of viability reporter where loss-of-signal activity can be used to understand changes in the cell viability. Furthermore, this assay endpoint can be referred to as a secondary readout, because this assay has produced multiple assay endpoints where this one serves a viability function. To generalize the intended target to other relatable targets, this assay endpoint is annotated to the cell cycle intended target family, where the subfamily is cytotoxicity.",, , , ,,,Active,43.5605399088032,1.602079753698863,64.76584801501798,1.81134605635659,4.53166577259249,34.1261451642,percent_activity,1.90308998699194,27.1899946355549,"[""Only highest conc above baseline, active"",""Less than 50% efficacy"",""Only highest conc above baseline, active"",""Less than 50% efficacy""]",1.83888930421351,1.76844067769225,1.69206573933758,20,cell cycle
UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist,"Data from the assay component UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist was analyzed into 1 assay endpoint. 
This assay endpoint, UPITT_HCI_U2OS_AR_TIF2_Nucleoli_Cytoplasm_Ratio_Agonist, was analyzed in the positive fitting direction relative to DMSO as the baseline of activity. 
Using a type of binding reporter, measures of receptor for gain-of-signal activity can be used to understand the binding at the pathway-level as it relates to the gene AR.",, , , ,,,Active,27.2858196726991,1.3642909836349548,101.5443987483373,2.00665597245004,2.03792638311569,28.3792475789577,percent_activity,2,20,"[""Only highest conc above baseline, active"",""Only highest conc above baseline, active""]",2.0614752303285,1.93922396903075,1.88737498276838,19.993499755859375,nuclear receptor